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There is a growing body of evidence indicating developmental disturbances to the 
glutamatergic system may underlie the pathogenesis of schizophrenia. Genetic and 
environmental studies indicate schizophrenia is associated with reduced glutamatergic 
signalling, in particular via the primary ionotropic N-methyl-D-aspartate (NMDA) 
glutamate receptor. Therefore, upregulation of NMDA receptor activity is proposed to 
be a novel avenue for the treatment of schizophrenia. Group 1 metabotropic glutamate 
receptors (mGluR), which include mGluR1 and mGluR5, are homodimeric G-protein 
coupled receptors that co-localise with and in-directly potentiate NMDA receptor 
currents. Therefore, group 1 mGluRs have been implicated in the pathology of 
schizophrenia and identified as a novel treatment target. The aim of this thesis was to 
assess group 1 mGluRs, particularly the dimeric and monomeric forms, in the 
neurodevelopment, pathology and treatment of schizophrenia. In addition, this thesis 
aimed to identify the neurochemical changes induced by treatment with the mGluR5 
positive allosteric modulator, CDPPB (3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-
yl)benzamide), in an attempt to better understand its potential preclinical antipsychotic 
efficacy. 
 
Building on recent studies from our lab identifying altered group I mGluRs in the 
prefrontal cortex and hippocampus in schizophrenia, Chapter 2 aimed to explore 
potential glutamatergic deficits in the nucleus accumbens in schizophrenia, a region 
believed to be central to schizophrenia pathology and receives glutamatergic 
projections from the prefrontal cortex and hippocampus. Using the largest nucleus 
accumbens postmortem cohort to date (n=30 control/30 schizophrenia), we report that 
protein expression of dimeric and monomeric mGluR1 and mGluR5 as well as their 
endogenous regulators, Norbin and Homer1b/c, in addition to the NMDA receptor 
subunits, NR1, NR2A and NR2B were not altered in schizophrenia. Collectively, these 
findings suggest the proteins may be altered in a brain-region specific manner, 
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particularly regions associated with higher order cognitive functions, such as the 
prefrontal cortex and hippocampus.  
 
Chapter 3 aimed to investigate the protein expression of group 1 mGluRs, Norbin, 
Homer1a and Homer1b/c in the nucleus accumbens following antipsychotic treatment, 
using an established and clinically relevant rodent model. Adult rats were orally 
administered daily doses of the typical antipsychotic, haloperidol (0.3 mg/kg), the 
atypical antipsychotic, aripiprazole (2.25 mg/kg) or vehicle for 1- or 10-weeks. Although 
group 1 mGluR expression was not altered following antipsychotic treatment, 1-week 
treatment with haloperidol and aripiprazole increased Norbin and Homer1a protein 
levels, respectively. Furthermore, Norbin protein expression was increased following 10-
week aripiprazole treatment. The observed differential temporal changes in Norbin and 
Homer1a protein expression following antipsychotic treatment, may influence group 1 
mGluR localisation and signalling which may partially mediate the therapeutic effects of 
haloperidol and aripiprazole. 
 
Chapter 4 aimed to investigate the neurodevelopmental expression of dimeric and 
monomeric group 1 mGluRs, at critical neurodevelopmental time-points (postnatal day 
(PN) 12, 35 and 96) in the perinatal phencyclidine (PCP) model of schizophrenia, to 
provide insight into their possible role in the development of schizophrenia, but also 
gain perspective into potential treatment windows for targeting mGluR5. We report in 
the prefrontal cortex, hippocampus and nucleus accumbens, dimeric mGluR5 remained 
relatively stable throughout PN12-PN96, however monomeric mGluR5 was abundantly 
expressed at PN12 and substantially declined at PN36 and PN96. In contrast, mGluR1 
monomer was consistently expressed throughout the time-points. Perinatal PCP 
treatment increased dimeric mGluR5 levels in the frontal cortex and hippocampus, 
however decreased hippocampal mGluR1 dimer levels at PN12. The early alterations 
observed to group 1 mGluR expression in this model, may contribute to the 
neurodevelopmental disruptions observed in this model and schizophrenia 
pathogenesis. Furthermore, these findings indicate group 1 mGluRs exhibit unique 
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dimeric and monomeric neurodevelopmental expression patterns, which may have 
functional implications for their signalling and pharmacology.  
 
There has been recent focus on group 1 mGluRs as therapeutic targets for treating 
schizophrenia. In particular, mGluR5 PAMs such as CDPPB, have shown encouraging 
efficacy in attenuating schizophrenia-like behaviours analogous to all symptom 
domains, in rodent models. Recent studies examining the efficacy of CDPPB indicate 
administration at adolescence may attenuate the development of schizophrenia-like 
behaviours at adulthood, particularly cognitive function.  Chapter 5 aimed to examine 
the short- and long-term neurochemical effects following adolescent CDPPB treatment. 
Immunoblot analysis of the adolescent hippocampus revealed CDPPB treatment 
increased mGluR5, NMDA receptor subunit (NR1 and NR2A) and AMPA receptor subunit 
(GluA1 and GluA2) expression. However, these changes were not observed at adulthood 
or in the frontal cortex. These findings suggest adolescent CDPPB treatment may induce 
brain-region specific effects on glutamatergic tone, which do not extend to adulthood. 
Further understanding the neurochemical changes caused by mGluR5 positive allosteric 
modulation, will improve drug design, ensuring their clinical suitability and efficacy.  
 
Collectively, this thesis adds to the current body of research investigating the role of 
group 1 mGluRs in the pathology, current and potentially future treatment of 
schizophrenia. This work builds from the human neurobiology and progresses towards 
neurodevelopmental, neuropharmacological, ultimately culminating in a novel 
treatment strategy for schizophrenia, using a rodent model. Unravelling the 
neurochemical changes that do or do not characterise schizophrenia and those 
important for therapeutic efficacy, are essential in developing our understanding of 
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Schizophrenia is a complex psychiatric disorder, which causes a lifetime affliction for 
affected individuals. The prevalence of schizophrenia is approximately 0.7% of the 
world’s population, with onset of symptoms occurring in early adulthood of males and 
slightly later in females (Saha et al., 2005). Schizophrenia is diagnosed according to the 
Diagnostic and Statistical Manual of Mental Disorders and is centred on the profile of an 
individual’s symptoms. Symptoms of schizophrenia include positive (e.g. hallucinations 
and delusions) and negative (e.g. depression, anxiety, social withdrawal and anhedonia), 
with many patients also experiencing cognitive deficits (e.g. memory and learning 
deficits) (Lewis and Lieberman, 2000). Cognitive impairments associated with 
schizophrenia have shown to contribute to poor functional outcomes and are now 
considered core to schizophrenia pathology (Green, 2006). Whilst antipsychotic drugs 
are primarily used to treat the positive symptoms associated with schizophrenia, the 
negative and cognitive symptoms are not adequately addressed by current treatments 
(Buchanan et al., 2005; Kirkpatrick et al., 2006). Therefore, it is vital to develop an 
understanding of schizophrenia to enable the advancement of more effective 
treatments, particularly for associated cognitive impairments. 
1.1.1 The Pathogenesis and Neurodevelopment Hypothesis of Schizophrenia 
Despite the classification of schizophrenia over 100 years ago, its cause remains elusive. 
It has been postulated that the genesis of schizophrenia begins before the onset of 
classical symptoms, giving rise to the neurodevelopmental hypothesis of schizophrenia. 
The foundations of the neurodevelopmental hypothesis propose that disruptions during 
early development may underlie the pathogenesis of schizophrenia (McGrath et al., 
2003).  In support of this hypothesis, factors during fetal development such as hypoxia, 
maternal stress, malnutrition and maternal infection may cause increased risk of 
developing schizophrenia in later life (Brown, 2006; Brown and Susser, 2008; Cannon et 
al., 2002; Khashan et al., 2008).  Reports from epidemiological studies show increased 
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risk of schizophrenia in individuals exposed to famine or influenza in utero (Brown and 
Susser, 2002).  Furthermore, those born in winter or suffered birth complications have 
higher incidence of diagnosis, suggesting the influence of early environmental factors 
may increase the susceptibility of an individual to develop schizophrenia (Bradbury and 
Miller, 1985). In addition, retrospective studies indicate a schizophrenia prodrome 
characterised by delayed motor development, language difficulties and lower IQ 
(Schenkel and Silverstein, 2004; Woodberry et al., 2008). Collectively, this evidence 
supports a neurodevelopmental cause for the development of schizophrenia. 
 
Despite a known definitive cause, there is strong evidence an interaction of genetic and 
environmental factors contributes to the development of schizophrenia. In particular, 
genes involved in brain development and synaptic plasticity, such as neuregulin 1 
(NRG1) (Bakker et al., 2004), dysbindin (DTNBP1) (Schwab et al., 2003) and disrupted in 
schizophrenia 1 (DISC1) (Callicott et al., 2005) have been associated with schizophrenia. 
Whilst there are several risk alleles associated with schizophrenia, these genes are also 
often associated with other psychiatric disorders such as bipolar, attention deficit 
hyperactive disorder, autism and depression (Kilpinen et al., 2008; Wen et al., 2016). No 
single gene has been identified to be responsible for schizophrenia, and not all 
individuals exhibiting genetic traits are diagnosed with schizophrenia, suggesting the 
impact of additional factors. Whilst there are several candidate genes and known 
lifestyle factors, it is highly likely a combination of influences contribute to disrupted 
neurodevelopmental processes and consequently to the pathogenesis of schizophrenia. 
1.1.2 The Neurobiology of Schizophrenia 
The exact cause(s) of schizophrenia are not known and there remains no diagnostic 
marker or clear neuropathology, likely due to the heterogeneity of the disorder. 
However, one of the most consistent findings comes from in vivo imaging studies, where 
schizophrenia patients exhibit increased ventricular volume, accompanied by reduced 
temporal lobe volume (Wright et al., 2000). Postmortem studies consistently report 
reduced cortical inhibitory interneurons suggesting alterations in brain neurochemistry, 
particularly those systems that regulate excitatory and inhibitory tone (Lewis et al., 
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2012). Furthermore, it is apparent from the multitude of animal and human studies that 
the symptoms of schizophrenia are associated with alterations in neurotransmission.  
 
While several neurotransmitter systems are implicated in the pathogenesis of 
schizophrenia, it is widely accepted that altered subcortical dopamine is one important 
component (Howes and Kapur, 2009). Several studies have reported increased levels of 
the dopamine precursor, L-3,4-dihydroxyphenylalanine, in the striatum of schizophrenia 
patients, indicating increased dopamine production and storage in presynaptic vesicles 
(Meyer-Lindenberg et al., 2002; McGowan et al., 2004; Hietala et al., 1995, 1999; Howes 
et al., 2009; Lindström et al., 1999; Reith et al., 1994). Furthermore, all studies that have 
examined patients at a period of acute psychosis, observed elevated striatal presynaptic 
dopamine levels, signifying increased dopamine production may be involved in the 
pathogenesis of psychosis in schizophrenia (Hietala et al., 1995, 1999; Howes et al., 
2009; Lindström et al., 1999).  
 
Following evidence of increased dopamine production, studies have examined the 
release of dopamine using positron emission tomography (PET) and single photon 
emission computerised tomography imaging. These studies rely on the competitive 
binding of radiolabelled ligands to displace endogenous dopamine from dopamine 
receptors to in-directly measure extracellular dopamine concentrations (Laruelle, 2000). 
Several studies have investigated the release of dopamine in the striatum of 
schizophrenia and control patients prior to and following amphetamine administration. 
All studies reported no differences in baseline dopamine release between groups, 
however following amphetamine administration, schizophrenia patients exhibit 
significantly higher amounts of dopamine release (Laruelle et al., 1996; Breier et al., 
1997; Abi-Dargham et al., 1998). Furthermore, administration of amphetamine, which 
increases synaptic dopamine, has been demonstrated to exacerbate positive symptoms 
in several schizophrenia patients (Breier et al., 1997). These reports of increased 
sensitivity to amphetamine challenges support the hypothesis that patients are at 
increased susceptibility to dopamine sensitivity and further implicates subcortical 
dopamine imbalance in schizophrenia pathology.    
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In line with the evidence of dopaminergic abnormalities observed in schizophrenia, 
blockade of subcortical hyperdopaminergic states, predominantly via antagonism of the 
D2 receptor subtype, is the primary mechanism proposed for the therapeutic efficacy of 
many current antipsychotic drugs (Grace et al., 1997). All current antipsychotics have 
affinity for the D2 receptor, which is strongly correlated to their therapeutic ability to 
reduce positive symptoms (Agid et al., 2006).  Furthermore, current antipsychotics are 
thought to exert this effect via the ventral striatum, in particular the nucleus accumbens, 
making it a region of interest in the pathology and treatment of schizophrenia (Deutch 
et al., 1992; Deutch and Cameron, 1992).  
 
Although there is strong evidence for subcortical hyperdopaminergia, it cannot account 
entirely for the pathology of schizophrenia for several reasons. Firstly, D2 receptor 
targeting antipsychotics do not treat all symptoms. Current antipsychotics are primarily 
effective for treating positive symptoms, however they largely have little effect on 
negative and cognitive symptoms (Buchanan et al., 2005; Kirkpatrick et al., 2006). 
Furthermore, not all patients respond to current antipsychotics (termed treatment 
refractory schizophrenia) (Lindenmayer, 2000), which suggests other neurotransmitter 
systems are likely involved. In line with this, a recent imaging study examining a small 
cohort of schizophrenia patients (6-10/per group), reported those who responded to 
dopaminergic antipsychotics displayed elevated striatal dopamine synthesis, whilst non-
responding patients displayed dopamine levels similar to controls (Demjaha et al., 
2014). Furthermore, non-responding patients displayed elevated glutamatergic 
abnormalities in the anterior cingulate cortex, suggesting a subset of patients may 
possess a different underlying pathophysiology and may require a different avenue of 
treatment, possibly via targeting the glutamatergic system. Imaging studies, which have 
been able to differentiate sub-regional differences of dopamine metabolism and 
receptor binding, indicate that the nucleus accumbens may not show as exaggerated 
dopaminergic abnormalities as previously thought (Howes et al., 2009; Kegeles et al., 
2010). In line with this, recent postmortem studies examining the nucleus accumbens 
indicate that the rate limiting dopamine synthesis enzyme, tyrosine hydroxylase, is 
unchanged (McCollum et al., 2016; McCollum and Roberts, 2015). Furthermore, protein 
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expression of the vesicle glutamate transporter, VGLUT2 in the nucleus accumbens was 
reported to be elevated in schizophrenia subjects (McCollum and Roberts, 2015). In 
addition, increased asymmetric synapses, representative of glutamatergic projections 
have been observed within the core of the nucleus accumbens in schizophrenia, 
however these synapses showed reduced post-synaptic area (McCollum et al., 2015). 
Collectively, these studies provide evidence for the presence of glutamatergic 
abnormalities in the nucleus accumbens. Whilst this evidence is relatively recent, a 
plethora of earlier evidence has implicated the glutamatergic system in the 
pathophysiology of schizophrenia.  
1.2 Glutamate receptors 
The amino acid, glutamate, acts as the primary excitatory neurotransmitter in the 
central nervous system (CNS). Glutamate plays an integral role in a wide variety of 
neurodevelopmental processes including neurogenesis, neuronal migration and 
synaptogenesis. Furthermore, glutamate is involved in mature neuronal functions such 
as synaptic plasticity and neuronal signalling, processes that are disturbed in a range of 
disorders including schizophrenia (McDonald and Johnston, 1990; Pearce et al., 1987). 
 
Glutamate acts via two distinct receptor classes, ionotropic and metabotropic. 
Ionotropic receptors include the N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-
methylisoxazole-4-proprionic acid (AMPA) and kainate receptors (Goff and Wine, 1997). 
Activation of these receptors by glutamate causes a fast influx of Ca2+ or Na+ ions. The 
expression and activity of ionotropic glutamate receptors, in particular the NMDA 
receptor (discussed later in Section 1.3), has been vastly implicated in 
neurodevelopmental psychiatric disorders such as schizophrenia. The NMDA receptor is 
an assembly of heteromeric subunits, comprising at least one requisite NR1 subunit, in 
complex with NR2 and/or NR3 subunits, creating a variety of different NMDA receptor 
arrangements (Paoletti et al., 2013). The distinct composition and formation of these 
subunits can produce a diversity of functional and pharmacological characteristics (Flint 
et al., 1997; Kristiansen et al., 2007; Sheng et al., 1994).  
 
  
Jeremy Lum 25 
 
Although the NR1 subunit is obligatory for the NMDA receptor, it does not contain the 
glutamate binding site; rather it possesses a binding site for the co-activator, glycine.  It 
is the NR2 subunits that contain the glutamate-binding site to act as the primary 
activator and regulator of NMDA receptor function. There are four genes that encode 
the different NR2 subunits (GRIN2A-D), which exhibit different spatiotemporal 
regulation. The NR2C subunits are predominantly confined to the cerebellum and the 
NR2D subunits to the thalamus and brainstem (Watanabe et al., 1992; Wenzel et al., 
1997). However, the NR2A and NR2B subunits are abundantly expressed in the cortex, 
hippocampus and striatum, regions implicated in schizophrenia, making them of 
particular interest for schizophrenia research (Portera-Cailliau et al., 1996). In regards to 
the temporal expression of the NR2 subunits, rodent studies demonstrate NR2B and 
NR2D are the predominant subunits expressed in the embryonic brain (Monyer et al., 
1994; Ritter et al., 2002; Wenzel et al., 1997). NR2A mRNA and protein expression 
appear in the first few days following birth and steadily increase until it peaks at around 
three postnatal weeks of age. Similarly, NR2C expression does not appear until after the 
first week of postnatal development (Guilarte and McGlothan, 1998; Zhong et al., 1995). 
In contrast, NR2B mRNA and protein expression increases following birth, however 
plateaus within the first week of postnatal development, with high expression in 
forebrain regions (Portera-Cailliau et al., 1996; Sheng et al., 1994; Zhong et al., 1995).  
 
Similar to rodent studies, mRNA and protein examination of the human foetal brain has 
shown NR2B is the primary NR2 subunit expressed in the cortex. Cortical NR2B 
expression has been detected as early as eight weeks gestational age and progressively 
increases during gestation (Ritter et al., 2001). Within the hippocampus, NR2B mRNA 
expression reaches peak expression in the neonatal brain and slowly declines 
throughout development into adulthood (Law et al., 2003). In contrast, NR2A expression 
is low during gestation, however increases in expression following birth and remains 
constant throughout life (Law et al., 2003; Ritter et al., 2001). 
 
Glutamate also signals via the metabotropic glutamate receptors (mGluR). mGluRs are 
seven transmembrane domain proteins and belong to the Class C G-protein coupled 
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receptor family. mGluRs are sub-classified into three groups (I, II, III) based on their 
sequence homology, G-protein coupling and pharmacology. Group I mGluRs comprise 
of mGluR1 and mGluR5 and are located primarily on the post-synaptic membrane. They 
are positively coupled to Gq/G11, instigating the activation of phospholipase C (PLC) and 
a pathway of downstream responses, resulting in neuronal excitation. Group II mGluRs 
include mGluR2 and mGluR3, whereas mGluR4, mGluR6, mGluR7 and mGluR8 
encompass group III. Group II and III mGluRs are both negatively linked to adenylyl 
cyclase and generally expressed pre-synaptically where they modulate neurotransmitter 
release (Krivoy et al., 2008). 
1.3 The Hypoglutamatergic Hypothesis of Schizophrenia 
The first report of glutamate involvement in schizophrenia came almost 40 years ago, 
with reduced levels of glutamate in the cerebrospinal fluid of patients with 
schizophrenia (Kim et al., 1980). Whilst these initial reports were unable to be replicated 
(Korpi et al., 1987; Perry, 1982), the hypothesis that glutamate is implicated in the 
pathology of schizophrenia, is still at the forefront of schizophrenia research, due to an 
array of evidence from genetic, imaging, postmortem and animal studies.  
 
Hypofunction of the glutamatergic system is widely believed to be a driving force 
underlying the pathology of schizophrenia, at least in a subset of patients. In particular, 
the concept of NMDA receptor deficits has remained at the forefront of the hypothesis. 
As previously mentioned (Section 1.1.1), no single gene has been found to be 
responsible for schizophrenia, however several genes encoding the NR1 (GRIN1), NR2A 
(GRIN2A) and NR2B (GRIN2B) subunits of the NMDA receptor have been associated with 
the disorder (Demontis et al., 2011; Galehdari et al., 2009; Martucci et al., 2006; 
Miyatake et al., 2002; Qin et al., 2005; Tang et al., 2006). Furthermore, a variety of 
candidate or high-risk genes have been associated with schizophrenia, such as NRG1 
(Bakker et al., 2004; Fukui et al., 2006; Munafò et al., 2006; Stefansson et al., 2002; 
Williams et al., 2003), DISC1 (Callicott et al., 2005; Millar et al., 2000, 2001) and DTNBP1 
(Schwab et al., 2003; Straub et al., 2002; Williams et al., 2004). Neuregulin 1, DISC1 and 
dysbindin have been demonstrated to directly or in-directly regulate the glutamatergic 
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system, in particular NMDA receptor activity. Neuregulin 1 and DISC1 co-localise with 
NMDA receptors in the post-synaptic density and their respective activity has been 
shown to regulate the expression and activity of the NMDA receptor (Bjarnadottir et al., 
2007; Hahn et al., 2006; Wei et al., 2014). In addition, dysbindin interacts with proteins 
responsible for synaptic glutamate release and may consequently influence NMDA 
receptor function (Saggu et al., 2013). Collectively, these studies suggest dysfunction of 
the NMDA receptor may be a convergence point for the various genes associated with 
schizophrenia (Snyder and Gao, 2013; Banjeree et al, 2010). 
 
Complimentary to genetic studies, investigations of the NMDA receptor in human 
postmortem studies support NMDA receptor abnormalities in schizophrenia.  The 
majority of studies have focused on the prefrontal cortex and hippocampus, with several 
studies reporting reduced NR1 mRNA and/or protein expression in these two regions 
(Beneyto and Meador-Woodruff, 2008a; Errico et al., 2013; Hahn et al., 2006; Weickert 
et al., 2013), although it should be noted there are also reports of no changes in other 
cohort studies (Emamian et al., 2004; Henson et al., 2008; Kristiansen et al., 2006; 
Kristiansen et al., 2010; Le Corre et al., 2000) and an isolated report of increased NR1 
mRNA expression in an elderly cohort (Dracheva et al., 2001). Findings regarding the 
NR2 subunits in schizophrenia are inconsistent, with reports of increased, decreased and 
no change in NR2A and NR2B mRNA or protein expression in the prefrontal cortex and 
hippocampus (for detailed review see Geddes et al., 2011). In subcortical regions such 
as the nucleus accumbens, studies investigating NMDA receptor subunit mRNA 
expression and binding have reported no differences between schizophrenia and 
unaffected subjects (Aparicio-Legarza et al., 1998; Meador-Woodruff et al., 2001; Noga 
et al., 1997). However, no study to date has examined the protein expression of NMDA 
receptor subunits in the nucleus accumbens, despite recent reports suggesting 
glutamatergic alterations in this region (discussed in Section 1.1.2)(McCollum et al., 
2015; McCollum and Roberts, 2015). Collectively, postmortem results can be conflicting 
dependent on the study, brain-region and target variable (mRNA or protein). 
Discrepancies within the same brain region could reflect cohort specific factors, in 
addition to technical factors across laboratories. Furthermore, it is widely accepted that 
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mRNA levels do not generally indicate protein levels, which may explain differences 
between mRNA and protein measures (Greenbaum et al., 2003). Whilst a clear trend 
does not seem apparent, a recent meta-analysis of NR1 mRNA and protein expression 
in the cortex of schizophrenia postmortem studies indicated a significant reduction in 
schizophrenia (Catts et al., 2016). Furthermore, the authors concluded a sample size of 
30 subjects per group is required to detect statistical significance based on the effect 
sizes, at least in the cortex, suggesting many previous studies, which used sample sizes 
as low as 6 per group may be underpowered (Catts et al., 2016).  
 
One of the strongest pieces of evidence supporting the NMDA receptor hypofunction 
hypothesis stems from the observation that NMDA receptor antagonists such as 
phencyclidine (PCP) and ketamine induce positive, negative and cognitive 
schizophrenia-like symptoms in healthy human subjects (Cohen et al., 1962; Cosgrove 
and Newell, 1991; Javitt and Zukin, 1991; Lahti et al., 1995). Furthermore, these 
compounds can exacerbate these symptoms in schizophrenia subjects (Javitt and Zukin, 
1991). Even at relatively low doses, PCP can produce psychotic and progressive 
withdrawal similar to the negative symptoms associated with schizophrenia (Luby et al., 
1959). Chronic recreational users of PCP are reported to show impaired cognitive 
performance, similar to those associated with schizophrenia (Cosgrove and Newell, 
1991; Javitt and Zukin, 1991). Furthermore, PET imaging studies of chronic recreational 
PCP users suggests neuroanatomical similarities with schizophrenia subjects 
(Hertzmann et al., 1990). Collectively, these clinical observations suggest NMDA 
receptor blockade produces behaviours similar to schizophrenia and may provide insight 
into its underlying pathology.  
 
Ensuing from clinical observations of the effects of NMDA receptor antagonist 
administration, in particular PCP, a field of research was dedicated to establish an animal 
model of relevance to schizophrenia. In adult rodents, acute PCP treatment causes 
behaviours analogous with schizophrenia such as hyperlocomotion, social withdrawal, 
cognitive impairment and deficits in pre-pulse inhibition (Egerton et al., 2005; Kalinichev 
et al., 2008; Mansbach and Geyer, 1989; Sams-Dodd, 1995). Furthermore, acute 
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injection of PCP has been shown to increase dopamine release within the striatum 
(nucleus accumbens), a characteristic associated with schizophrenia pathology (Carboni 
et al., 1989). However, acute PCP treatment does not recapitulate the chronic manner 
or neurodevelopmental trajectory associated with schizophrenia.  
 
Repeated administration of PCP to rodents, generally including twice-daily PCP 
administration for 7-14 days, with a 7-day washout period before testing, in adult 
rodents has shown to produce behaviours analogous to schizophrenia. A major 
advantage of the PCP model is its ability to recapitulate negative symptoms, which are 
not observed in amphetamine models. Chronic PCP treatment has been shown to induce 
social behaviour deficits (Lee et al., 2005; Qiao et al., 2001; Sams-Dodd, 1996, 1998). 
Furthermore, social withdrawal deficits have been shown to be reversed by treatment 
with the atypical antipsychotic, clozapine (Qiao et al., 2001; Sams-Dodd, 1998). In 
addition, many cognitive behavioural impairments have been observed following 
chronic PCP treatment, including deficits in reversal learning (Abdul-Monim et al., 2006; 
Idris et al., 2010; McLean et al., 2010), novel object recognition tasks (Grayson et al., 
2007; Idris et al., 2010), episodic memory (Le Cozannet et al., 2010), attentional set 
shifting (Broberg et al., 2009; Goetghebeur and Dias, 2009), spatial learning and memory 
(Beraki et al., 2008; Jentsch et al., 1997). In fact, chronic PCP administration may better 
mimic the schizophrenia pathology compared to acute treatment, as behaviours are 
observed days or weeks following cessation of PCP treatment.  
 
Acute and chronic administration of PCP in adult rats induces schizophrenia-like 
behaviour. However, a limitation to these models is they do not possess the construct 
validity for the neurodevelopmental hypothesis of schizophrenia. The concept of the 
neurodevelopmental hypothesis suggests that early insult, may give rise to the 
pathology of schizophrenia. Considering, the critical role of the NMDA receptor in 
neurodevelopment, and the fact environmental insults and candidate genes associated 
with schizophrenia (NRG1, DISC1 and DTNBP1) converge to disrupt NMDA receptor 
activity during development it is conceivable that early insult to NMDA receptor 
expression or activity during critical stages of neurodevelopment may contribute to the 
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pathogenesis of schizophrenia. In an effort to address this, a perinatal PCP rat model 
was established, whereby pups are treated with PCP (10 mg/kg) on PN7, 9 and 11 (Wang 
et al., 2001). This model is the most widely used perinatal PCP model and has been 
extensively characterised with long lasting behavioural and molecular deficits that are 
associated with schizophrenia. 
 
PCP administration (10 mg/kg) at PN7, 9 and 11 has repeatedly demonstrated to cause 
pre-pulse inhibition deficits at adolescence (PN24-28) (Anastasio and Johnson, 2008a; 
Wang et al., 2001, 2003). Furthermore, perinatal PCP treatment induces locomotor 
sensitisation at adulthood following an acute PCP injection (Anastasio and Johnson, 
2008a; Wang et al., 2001). In addition, pre-pulse inhibition deficits and PCP-induced 
hyperlocomotive behaviour have been attenuated with acute antipsychotic treatment, 
demonstarting predictive validity in this model (Anastasio and Johnson, 2008a). 
Moreover, cognitive deficits have been repeatedly reported in adult rats treated with 
PCP during the perinatal period, including deficits in social recognition, cognitive 
flexibility in set-shifting tasks and acquisition and performance of spatial learning tasks 
(Broberg et al., 2009; Depoortère et al., 2005; Harich et al., 2007; Wiley et al., 2003). 
Furthermore, reduced performance in Morris water maze tasks has been observed in 
this model, which was attenuated with chronic treatment of the glutamate co-agonist, 
D-serine, suggesting that reduced glutamatergic signalling may underpin the cognitive 
deficits in this model (Andersen and Pouzet, 2004). In line with this, altered NR1 and 
NR2A subunit expression has been reported in the frontal cortex and striatum (Anastasio 
and Johnson, 2008b, 2008a; du Bois et al., 2012; Wang et al., 2001). Reports from our 
laboratory have shown that this model also produces alterations in NMDA and GABAA 
receptor binding in the frontal cortex, hippocampus and thalamus, throughout critical 
stages of neurodevelopment, suggesting an imbalance of the major excitatory and 
inhibitory neurotransmitter systems (du Bois et al., 2009). Furthermore, deficits in 
neuregulin1/erbB4 signalling, a major regulator of excitatory/inhibitory 
neurotransmitter tone and a pathway implicated in the pathology of schizophrenia have 
been observed in various brain regions of rodents treated with PCP during the perinatal 
period (du Bois et al., 2012). This model has also shown changes to the dopaminergic 
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system, with reports indicating developmental changes to D2 receptor binding and 
expression of the dopamine synthesis enzyme, tyrosine hydroxylase (du Bois et al., 
2008). Collectively, the aforementioned studies suggest perinatal PCP treatment 
produces behavioural and neurochemical changes associated with schizophrenia 
pathology. Furthermore, these abnormalities are present weeks and months following 
the initial insult period, indicating permanent developmental changes to the structure 
and circuitry of the brain. Therefore, perinatal antagonism of the NMDA receptor 
produces a valuable model in which to study the neurodevelopmental and 
hypoglutamatergic hypothesis of schizophrenia.  
 
Collectively, there are several converging lines of evidence implicating reduced NMDA 
receptor activity in schizophrenia. Based on this evidence, exploring avenues to improve 
NMDA receptor activity has become a highly attractive area of research. In line with this, 
treatment with co-agonists such as glycine, D-serine and D-cycloserine have shown 
promise in the management of schizophrenia symptoms (Labrie and Roder, 2010). 
Furthermore, the potential of mGluRs to modulate NMDA receptor activity has been 
identified as a possible treatment opportunity (Vinson and Conn, 2012); group 1 mGluRs 
are of particular interest as they share a physical interaction with the NMDA receptor. 
Group 1 mGluRs form physical associations with the NMDA receptor in various brain 
regions including the hippocampus, prefrontal cortex and striatum, regions strongly 
associated with schizophrenia pathology (Alagarsamy et al., 2002; Henry et al., 2002; 
Luccini et al., 2007). Group 1 mGluRs and the NMDA receptor are co-localised on 
postsynaptic membranes and their physical link is supported by the scaffolding proteins 
Homer, SH3 and multiple ankyrin repeat domains (SHANK), guanylate-kinase-associated 
protein (GKAP) and post-synaptic density 95 (PSD-95) (Tu et al., 1999). Furthermore, this 
physical link provides a functional relationship, whereby mGluR1/5 activity indirectly 
regulates NMDA receptor currents (discussed in Section 1.4.2).  In addition, NMDA 
receptor activity has been shown to modulate the activity of group 1 mGluRs 
(Alagarsamy et al., 2005). However, this begs the question, if NMDA receptor activity is 
implicated in the pathology of schizophrenia, do group 1 mGluRs also play a role and 
provide a potential new avenue for treatment?  
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1.4 Group 1 mGluRs 
1.4.1 Expression and Splice Variants 
Group 1 mGluRs are widely expressed throughout the CNS, however are most abundant 
within the cortex, hippocampus, striatum and nucleus accumbens, brain regions 
implicated in the pathology and treatment of schizophrenia (Kerner et al., 1997; Carmelo 
Romano et al., 1996; Shigemoto et al., 1993, 1992). Whilst both mGluR1 and mGluR5 
are expressed in neurons, only mGluR5 is expressed in glial cells, including 
oligodendrocytes, neural stem cells, microglia and astrocytes (Byrnes et al., 2009; Luyt 
et al., 2003; Romano et al., 1996). Furthermore, mGluR1 and mGluR5 are both 
predominately expressed post-synaptically, however there is evidence that mGluR1 and 
mGluR5 may additionally be expressed pre-synaptically and modulate glutamate release 
(Gereau Iv and Conn, 1995; Mannaioni et al., 2001).  
 
mGluR1 and mGluR5 are encoded by the GRM1 and GRM5 genes, respectively, and can 
undergo alternate splicing. Splicing of the mGluR1 mRNA, gives rise to 5 distinct C-
terminal variants: mGluR1a-e; however in rats an additional splice variant mGluR1f has 
been identified which produces an identical protein to mGluR1b (Hermans and Challiss, 
2001). mGluR1a and mGluR1b are the most abundant splice variants, with mGluR1b 
displaying a truncated C-terminal and slower Ca2+ kinetics, than the mGluR1a variant 
(Pin et al., 1992). Meanwhile, mGluR5 consists of two primary splice variants, mGluR5a 
and mGluR5b, with mGluR5b containing a 32 amino acid insert within the C-terminus. 
Pharmacological studies show negligible differences between mGluR5a and mGluR5b 
with both displaying similar functional characteristics to mGluR1a (Joly et al., 1995).  
1.4.2 Signalling 
mGluR1 and mGluR5 positively couple to Gq/11 and subsequent agonist-induced 
stimulation causes activation of phospholipase C, consequently initiating 
phosphatidylinositol 4,5-biphosphate (PIP2) hydrolysis into inositol 1,4,5 triphosphate 
(IP3) and diacyl-glycerol (DAG). This process leads to IP3-mediated Ca2+ release from 
intracellular stores and DAG-mediated activation of protein kinase C (PKC). Activation of 
PKC can lead to a wide range of signalling processes, such as the activation of 
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mammalian target of rapamycin (mTOR) pathways, cAMP response element-binding 
protein (CREB) and brain-derived neurotropic factor (BDNF) production, signalling 
molecules which have all been implicated in neuropsychiatric disorders (Niswender and 
Conn, 2010). Furthermore, activation of PKC can stimulate proline-rich tyrosine 
kinase/cell adhesion kinase (Pyk2/CAKβ) to recruit Src, which in turn can phosphorylate 
tyrosine residues on the NMDA receptor, increasing channel open probability 
(Groveman et al., 2012; Lu et al., 1999) (Figure 1.1). Whilst it was previously thought 
mGluR5, not mGluR1, was responsible for potentiating NMDA receptor currents (Awad 
et al., 2000; Doherty et al., 1997, 2000; Jia et al., 1998; Mannaioni et al., 2001; Pisani et 
al., 2001), this is probably due to the fact the earlier investigated systems did not express 
high levels of mGluR1, expressed alternative splice variants (mGluR1b/c, not mGluR1a) 
or lacked co-localisation of mGluR1 and NMDA receptors. However, in CA3 (Cornu 
Ammonis) neurons, where mGluR1 is highly expressed and co-localised with NMDA 
receptors, mGluR1 has been shown to potentiate NMDA receptor currents (Benquet et 
al., 2002). Furthermore, mGluR1 can also activate NMDA receptors via a G-protein 
independent pathway, likely due to the binding of the adaptor protein, β-arrestin and 
subsequent Src recruitment, which has previously been reported for other mGluRs 
(Lefkowitz and Shenoy, 2005).  In addition, there is evidence group 1 mGluRs may also 
possess a capacity to activate alternate G-protein signalling pathways. mGluR1a was 
shown to activate phosphoinositide hydrolysis and cAMP accumulation in transfected 
Xenopus oocytes, Chinese hamster ovary (CHO), baby hamster kidney (BHK) and Human 
embryonic kidney 293 (HEK293) cells (Aramori and Nakanishi, 1992; Francesconi and 
Duvoisin, 1998; Hermans et al., 2000; Parmentier et al., 1998; Thomsen, 1996). Similarly, 
mGluR5 was shown to stimulate cAMP accumulation in oocytes and Lilly Laboratories 
Cell-Porcine Kidney (LLC-PK1) cells (Joly et al., 1995), but not in CHO cells, suggesting 
possible coupling to the Gs protein-coupled receptor pathway (Abe et al., 1992). 
Collectively, the evidence suggests mGluR1 and mGluR5 signalling is more complex than 
previously thought and appears to depend on cell types, in addition to receptor 
expression levels.  
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Figure 1.1: Illustration of G-protein-dependent and independent potentiation of the 
NMDA receptor. mGluR1 and mGluR5 are physically linked to the NMDA receptor 
(NMDAR) via the scaffolding proteins Homer, SH3 and multiple ankyrin repeat domains 
(SHANK), guanylate-kinase-associated protein (GKAP) and post-synaptic density 95 
(PSD-95). Glutamate stimulated activation of mGluR1 or mGluR5 activates the positively 
coupled G-protein, Gq/11, consequently stimulating phospholipase C (PLC) and 
production of 1,4,5-triphosphate (IP3) and diacylglycerol (DAG), causing release of 
endoplasmic reticulum calcium (Ca2+) stores. A rise in intracellular calcium activates 
protein-kinase C (PKC) and subsequently phosphorylates proline-rich tyrosine 
kinase/cell adhesion kinase β (Pyk2/CAKβ) and consequently Src, which in turn 
phosphorylates tyrosine residues of the NMDA receptor, increasing open channel 
probability. Alternatively, mGluR1 can potentiation the NMDA receptor independent of 
G-protein pathways, presumably via coupling to β-arrestin and subsequent Src 
recruitment. 
 
Whilst G-protein coupled receptors (GPCRs) are typically considered responsible for 
transmitting extracellular stimuli to intracellular responses, many GPCRs are also found 
on intracellular membranes. In addition to group 1 mGluR expression on the cell 
membrane, they are also localised on the endoplasmic reticulum and nuclear membrane 
(Hubert et al., 2001a; López-Bendito et al., 2002; Petralia et al., 1997). In fact, a large 
proportion of mGluR1 (40-60%) and mGluR5 (60-90%) are located on intracellular 
membranes, rather than the plasma membrane, depending on the brain region 
investigated (Hubert et al., 2001; Lopez-Bendito et al., 2002; O’Malley et al., 2003).  
O’Malley and colleagues have identified unique roles for group 1 mGluRs, dependent on 
their cellular localisation, in particular the nuclear membrane, adding further complexity 
to their signalling and function. Intracellular group 1 mGluRs are able to be activated by 
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intracellular glutamate entering via ion dependent transporters/exchangers or released 
via the endoplasmic reticulum (Jong et al., 2005; Kumar et al., 2008). Furthermore, 
subsequent activation of nuclear mGluR1 and mGluR5 is capable of activating unique 
Ca2+ signatures and signalling pathways to their cell surface counterparts. Specific 
activation of intracellular mGluR1 or mGluR5 in cultured striatal neurons was shown to 
result in phosphorylation of ERK1/2, Elk-1 and CAMKII with intracellular mGluR5 
activation also causing upregulation of transcriptional factors involved in neuronal 
growth, survival and synaptic plasticity (Jong et al., 2007; Jong et al., 2009). In addition, 
using hippocampal slices, activation of intracellular mGluR5 was shown to play a role in 
long-term depression (LTD), however not potentiation (Purgert et al., 2014). 
Collectively, these studies highlight the unique signalling and functional consequences 
of group 1 mGluRs, dependent on their subcellular localisation.  
1.4.3 Neurodevelopmental Profile 
Group 1 mGluRs are required for normal neurodevelopment with mGluR1 and mGluR5 
knock-out (KO) mice showing various signalling and behavioural deficits (discussed later 
in Section 1.6.1). mGluR1 and mGluR5 are primarily responsible for the high level of PIP2 
hydrolysis and PKC activation during CNS development, which is required for cell growth 
and differentiation (Berridge, 1993).  Furthermore, group 1 mGluRs play a role in LTD 
and long-term potentiation (LTP), the underlying processes involved in synapse 
formation. Group 1 mGluRs, in particular mGluR5, have shown to be highly expressed 
by neuroprogenitor cells where they play a role in the survival and proliferation of neural 
stem cells within the subventricular zone and dentate gyrus (Di Giorgi Gerevini et al., 
2004; Di Giorgi-Gerevini et al., 2005).  In line with this, mGluR1 and mGluR5 mRNA and 
protein expression has been detected in the CNS of human and rodent embryos. 
Postnatal mGluR1a expression in the CNS appears to increase from birth for the first two 
weeks of rodent neurodevelopment, however reaches a plateau thereafter (Casabona 
et al., 1997; Catania et al., 1994; Di Giorgi Gerevini et al., 2004)(Table 1.1). Whilst 
mGluR5 expression appears to be abundant in the first week of postnatal development 
in the rodent, it appears to plateau or decline at later adolescent and adult time points 
(Casabona et al., 1997; Catania et al., 1994; Di Giorgi Gerevini et al., 2004; Romano et 
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al., 1996). However, expression analysis showed this is likely due to a decline in the 
mGluR5a splice variant following birth, with mGluR5b remaining stable throughout 
postnatal stages (Romano et al., 2002). This may suggest there are functional differences 
between the mGluR5a and mGluR5b splice variants in regards to their role in 
neurodevelopmental processes. In line with this, homologous cells transfected with 
these splice variants suggest mGluR5a hinders neuronal maturation, whilst mGluR5b 
increases neurite growth (Mion et al., 2001), however little has been done to further 
identify functional differences. Furthermore, it appears mGluR5 undergoes functional 
signalling changes throughout the ageing process. Striatal slices collected from young 
rats (3 months) exhibit higher mGluR5 protein levels than old (24 months) rats 
(Domenici et al., 2003). In addition, this decline of mGluR5 protein expression is 
associated with reduced functionality as aged rats displayed lower phosphoinositide 
turnover in response to the mGluR5 specific agonist, CHPG, as well as decreased ability 
to potentiate NMDA receptor mediated currents (Domenici et al., 2003). This age-
dependent decline of mGluR5 expression and signalling was also associated with a 
decline in phospholipase C-β1, indicating an age dependent loss of mGluR5 signalling 
partners. In line with this, Kaja and colleagues reported a change in the ratio of short 
and long forms of Homer1, a multivalent complex responsible for the association of 
mGluR5 and IP3 signalling, in the aged forebrain (Kaja et al., 2013). Collectively, these 
results suggest group 1 mGluR expression and downstream signalling display changes 
throughout postnatal development and ageing. 
1.4.4 Structure 
Group 1 mGluRs share similar primary, secondary, tertiary and quaternary structure. 
Group 1 mGluRs possess a large N-terminus that encases a venus-fly-trap domain for 
agonist binding (Parmentier et al., 1998). The N-terminus links to a 7-transmembrane 
domain, which plays a role in activation of coupled G-proteins. Furthermore, group 1 
mGluRs possess a C-terminus tail; this region exhibits the largest variation between 
mGluR1 and mGluR5. 
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Reported findings Reference 
Human Studies 
Marginal zone, 
cortical plate and 
ventricular zone 
Gestational ages (GA): 9, 
10, 13, 16, 17, 20, 22, 23, 
25, 29, 31, 36 and 40 weeks 
(n=1/time point) 
Postnatal ages: 3 weeks, 2 
months, 7 months and 8 





 mGluR1a expression was detected in cortical plate at all time-points 
 mGluR1a expression was detected in the marginal zone at 36-40 weeks gestational age 
and <7 months postnatal. 
 mGluR5 was strongly expressed in marginal zone, cortical plate and ventricular zone at 
all gestational and postnatal time points 
(Boer et 
al., 2010) 
Temporal cortex Gestational ages: 13 weeks   
Postnatal ages: 2 months 




mGluR5 (monomer)  
 mGluR1a and mGluR5 expression were highest at 13 weeks gestation and decreased at 
2 months postnatal, where it was similar at 30 years. 
Hippocampus Gestational ages: 
9-11 weeks (n=9) 
14-16 weeks (n=10) 
2-24 weeks (n=9) 










 mGluR5 protein significantly increased progressively with all ages  
Rodent Studies 
Sprague-Dawley rats;  
Cortex, striatum, 
hippocampus 
(dentate gyrus and 
internal granular 
layer) 
Postnatal day (PND) 1, 3, 7, 






 Low level of mGluR1 expression at PND0 in all brain regions; expression gradually 
increased until PND21, where adulthood (PND60) levels were reached.  
 mGluR5 was highly expressed in the cortex and striatum at PND1 and slowly declined 
over the first 3 weeks of postnatal development and remained constant until PND60. 




Wistar Rats; Cortex, 
hippocampus, 
olfactory bulb 
PND3, 7, 14, 21, 28 and 35 RT-PCR: mGluR5a 
and mGluR5b 
 mGluR5a was the abundant form in olfactory bulb at all time-points examined, 
compared to mGluR5b 
 mGluR5a was predominant form at PND3 and 7 in cortex and hippocampus 











bulb and cerebellum 
 
PND7 and adult 
 
 







 mGluR5a was higher at PND7 than adulthood. 
 mGluR5b mRNA levels were similar at PND7 and adulthood. 
 
 mGluR5 protein expression (unable to differentiate between splice variants) increased 
in cortex, hippocampus, striatum, hypothalamus and brainstem from PND0-11 and 
then decreased at PND18, where levels remained relatively stable until PND70.  
 mGluR5 levels in the cerebellum at PND0 and decreased throughout the time-points 
investigated 











PND9 and 2 months (adult) Western blot: 
mGluR1a and 
mGluR5 (monomer) 
 mGluR1a expression was higher at PND9 than adulthood in the hypothalamus, 
olfactory bulb and hippocampus. 
 mGluR1a expression was higher at in the adult cerebellum than at PND9 in the 
hypothalamus, olfactory bulb and hippocampus. 
 No difference in mGluR1a protein levels were found between PND9 and adult corpus 
striatum and cerebral cortex  








bulb and cerebellum 
PND7 and adult  Western blot: 
mGluR5b 
(monomeric band) 
 mGluR5b protein levels were higher at adulthood than PND7 in the cortex and 
hippocampus.  
 mGluR5b protein levels were similar at PND7 and adulthood in the hypothalamus and 
striatum. 








Gestational day (GD) 12, 15 
and PND1, 10, 21  
RT-PCR: mGluR1a/b 
and mGluR5a 
 mGluR1a/b mRNA was detected at GD12.  
 mGluR1a/b mRNA increased from PND1-21 in the cortex and cerebellum, whilst in the 
hippocampus expression increased from PND1-10 and decreased between PND10-21. 






and monomer) and 
mGluR5 (monomer 
only)  
 mGluR1a protein expression was undetectable during embryonic development. 
 mGluR1a protein was detected at PND1 in all brain regions and increased with age in 
the cortex and cerebellum. However, in the hippocampus mGluR1a protein expression 
increased between PND1-10 and then decreased between PND10-21.  
 mGluR5 protein expression was detectable during embryonic development and 
expression peaked between PND1-10, but then declined at PND21, in all brain regions 
examined. 
Abbreviation: RT-PCR, real-time polymerase chain reaction; GA, gestational age, GD, gestational day; PND, postnatal day. 
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In addition to possessing the venus-fly trap domain, which acts as a site for agonist 
binding, the N-terminus of group 1 mGluRs contains cysteine residues capable of 
forming disulphide bridges and consequent homo- and hetero-dimers, a characteristic 
which appears to be conserved across all mGluRs (Romano et al., 2001).  Recent studies 
suggest mGluR1 and mGluR5 are capable of heterodimerisation with each other, 
however not the group 2 or 3 family of mGluRs (Doumazane et al., 2011). In addition, 
mGluR5 may also be capable of dimerisation with the adenosine A2A and dopamine, D2 
receptors (Fuxe et al., 2014; Popoli et al., 2001). The existence of mGluR1 and mGluR5 
homodimers was reported almost 20 years ago. Romano and colleagues first observed 
an mGluR5 band that was twice as large as its predicted molecular weight, under non-
reducing western blot conditions (Romano et al., 1996). The addition of reducing agents, 
dithiolthreitiol or 2-mercaptoethanol caused mGluR5 to migrate at its apparent 
molecular weight, indicating the breakdown of mGluR5 covalent disulphide bridges. In 
addition, treatment of the tissue with iodeoacetamide, which alkylates free sulfhydryls 
(preventing the ex vivo formation disulphide bonds), did not change appearance of 
these higher molecular weight species, indicating these species were not spontaneously 
forming postmortem. It is now clear mGluR1 and mGluR5 form homodimers within the 
endoplasmic reticulum and Golgi apparatus before transportation to various cellular 
locations such as the plasma, mitochondrial or nuclear membrane (Pin et al., 2003; 
Sergin et al., 2017). Collectively, these findings clearly show mGluR1 and mGluR5 are 
capable of homodimerisation and are natively expressed in this manner. Furthermore, 
dimerisation appears to be vital for agonist-induced signalling. El Moustaine and 
colleagues (2012) demonstrated although dimerisation of mGluRs is not required for G-
protein coupling, dimerisation is necessary for agonist-induced activation, rendering the 
monomeric form inactive to agonist-induced activation (Figure 1.2). In addition, it was 
demonstrated that binding of a positive allosteric modulator to a monomeric mGluR 
caused the subsequent activation of the G-protein in the absence of glutamate (El 
Moustaine et al., 2012). Furthermore, Kniazeff et al., (2004) demonstrated that whilst 
binding of glutamate to an mGluR5 protomer (monomeric subunit of dimeric complex) 
was sufficient to partially activate the receptor, ligand binding to both protomers 
consequently caused full activation. In light of this evidence, examining these receptors 
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Figure 1.2: Schematic of proposed activation of dimeric and monomeric mGluRs by 
orthosteric agonists and positive allosteric modulators. a. Binding of glutamate to a 
dimeric mGluR causes G-protein activation. b. Binding of a positive allosteric modulator 
to a dimeric mGluR in the absence of glutamate does not cause G-protein activation and 
c. requires the presence of glutamate, for subsequent G-protein activation. d. 
Glutamate binding to a monomeric mGluR does not result in G-protein activation, 
however e. a positive allosteric modulator can result in G-protein activation in the 
absence of glutamate. 
 
Group 1 mGluRs contain a 7-transmembrane domain, which has become of recent 
interest for drug discovery efforts. A large effort has focused on identifying compounds 
with allosteric modulatory properties for group 1 mGluRs, in particular mGluR5. 
Allosteric modulators bind in an alternate location (allosteric site) to the traditional 
orthosteric site (i.e. glutamate binding site), changing the conformation of the receptor 
and consequently up or down regulating the activation of the receptor by its orthostertic 
ligand. Allosteric modulators can alter the pharmacological characteristics of a receptor 
in a variety of ways, including increasing or decreasing the affinity of the orthosteric 
ligand or downstream signalling pathways of orthosteric ligands, or alter receptor 
activity, irrespective of orthosteric ligand binding (Christopoulos and Kenakin, 2002). 
There are several allosteric sites found within the 7-transmembrane region of group 1 
mGluRs, (Chen et al., 2008; O’Brien et al., 2003; Wu et al., 2014), providing many drug 
targets. Allosteric sites provide several key advantages over traditional orthosteric 
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ligands. One major advantage is that orthosteric sites tend to be conserved across 
receptor families; therefore, allosteric ligands provide greater target receptor specificity 
than their traditional orthosteric counterparts. Furthermore, allosteric modulators 
which do not display agonist activity rely on endogenous ligand activity, avoiding 
desensitisation or toxic effects observed with orthosteric ligands (Conn et al., 2009).  
 
The C-terminus of mGluR1 and mGluR5 contains multiple sites in which a multitude of 
proteins can directly interact and regulate receptor activity, signalling and localisation. 
As previously mentioned, mGluR1a and mGluR5a/b exhibit the longest C-terminus of 
the group 1 mGluR splice variants and are the most abundantly expressed in the brain. 
The longer C-terminus of these splice variants provides a region for direct protein 
interactions with various protein kinases and phosphatases. PKC is the most extensively 
investigated kinase associated with group 1 mGluRs and has been demonstrated to 
constitutively phosphorylate group 1 mGluRs. In addition, PKC is responsible for 
phosphorylation of mGluR1 and mGluR5 at several serine and threonine sites along the 
C-terminus upon agonist stimulation. Similar to many other G-protein coupled 
receptors, PKC-dependent phosphorylation of group 1 mGluRs exhibits a negative 
feedback loop to promote desensitisation, in response to prolonged agonist-induced 
stimulation. In addition, G-protein receptor kinase 2 (GRK2) has also shown to play a 
role in mGluR1/5 desensitisation via coupling the receptor to β-arrestin and 
consequently mediating clathrin coated endocytosis pathways. Furthermore, PKC 
phosphorylation of sites such as T695 and T681 are thought to reduce G-protein 
coupling and consequently reduce downstream group 1 mGluR signalling. It also appears 
that group 1 mGluR signalling is tightly regulated via Ca2+ sensitive molecules, as 
calmodulin (CaM) is capable of binding to PKC phosphorylation sites and prevent PKC 
phosphorylation. Although not as extensively investigated as serine and threonine 
phosphorylation, it has also been demonstrated that mGluR5 can undergo 
phosphorylation at its tyrosine residues in cultured striatal neurons. NMDA receptor 
activation has been shown to increase mGluR5 tyrosine residue phosphorylation, 
highlighting the important role the C-terminus of group 1 mGluRs has in receptor cross 
talk.  
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Collectively, these interactor proteins of the group 1 mGluR C-terminus can regulate 
cellular localisation, protein-protein association and internalisation. The family of 
Homer1 and Norbin proteins also interact with group 1 mGluRs. Furthermore, they have 
recently been implicated in the pathophysiology of schizophrenia and are of relevance 
to the present thesis. The association of Homer1 and Norbin with group 1 mGluRs and 
their relevance to schizophrenia and other neuropsychiatric disorders is reviewed 
below.  
1.5 Group 1 mGluR Interacting Partners-Homer1 and Norbin 
1.5.1 Homer1  
Brakeman and colleagues were the first to identify a group 1 mGluR endogenous 
regulator, in the form of Homer1, which contains a PDZ-domain for interaction with the 
C-terminus of group 1 mGluRs (Brakeman et al., 1997). Homer1 has three isoforms, 
dependent on gene splicing; Homer1a (vesl-1S) is the shortest of the splice variants (186 
amino acids) and is encoded by an immediate early gene. In addition to the short 
Homer1a isoform, Homer1 can also be alternatively spliced into the Homer1 long forms 
(vesl-1L); Homer1b and Homer1c (Shiraishi-Yamaguchi and Furuichi, 2007).  
 
Homer1 expression is mainly localised to glutamatergic excitatory synapses and 
regulated in response to synaptic activity. Homer1a expression is induced following 
synaptic activity in the form of LTP, synaptogenesis, ischemia and seizures (Brakeman et 
al., 1997; Kato et al., 1998). Meanwhile the long Homer1 isoforms are constitutively 
expressed.  Homer1 short and long forms share a common conserved enabled/VASP 
homology 1 (EVH1) domain structure, which is capable of direct interaction with group 
1 mGluRs (Brakeman et al., 1997). Furthermore, the long forms of Homer1 possess a 
carboxyl-terminal domain or multimerisation domain and contain a coiled-coil structure 
capable of forming homomeric or hetromeric interactions with a range of binding 
partners (Tadokoro et al., 1999; Xiao et al., 1998). One major binding partner of the long 
forms of Homer1 is the IP3 receptor, located on the membrane of the endoplasmic 
reticulum. Homer1b/c mediates the association of group 1 mGluRs and the IP3 receptor 
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to increase Ca2+ release from intracellular stores of (Tu et al., 1998). As Homer1a lacks a 
coiled-coil domain, it prevents facilitation of this process. Furthermore, Homer1a 
competitively binds to group 1 mGluRs to reduce this process, thereby acting in a 
dominant negative manner (Xiao et al., 1998). It is clear that Homer1 plays an important 
role in group 1 mGluR signalling and Ca2+ homeostasis and should be considered in this 
context when assessing mGluR function.  
1.5.2 Norbin/Neurochrondrin  
Norbin (rodent) or neurochondrin-1 (human) is one of the most recently identified 
endogenous regulators of group 1 mGluRs. Norbin is expressed in chondrocytes, 
osteoblasts and osteocytes, however in the CNS, it is thought to localise specifically to 
neurons (Ishiduka et al., 1999). Norbin is a cytosolic protein, widely distributed in 
excitatory dendritic spines at the post-synaptic density and co-localised with group 1 
mGluRs (Wang et al., 2009). A large majority of studies investigating Norbin have 
focused on its association with mGluR5, with no further investigation of its role with 
mGluR1, despite confirmation of a physical interaction. Norbin has been demonstrated 
to play a role in mGluR5 cell surface expression, with neuronal cultures overexpressing 
Norbin exhibiting increased surface mGluR5 (Wang et al., 2009). Furthermore, Norbin 
potentiates mGluR5 signalling; HEK293 cells transfected with Norbin exhibit increased 
mGluR5-stimulated inositol trisphosphate, ERK1/2 phosphorylation and intracellular 
Ca2+ release (Wang et al., 2009).  
 
Norbin is a relatively recently discovered protein and there are limited studies regarding 
its function. Deletion of Norbin in rodents causes death during early embryonic periods, 
indicating its importance in neuronal development (Mochizuki et al., 2003). Norbin 
mRNA expression in the mouse embryo can be detected as early as embryonic day (ED) 
10 where it is localised to the hindbrain (Mochizuki et al., 2003). mRNA and protein 
expression within the cortex has been detected at ED18, progressively increasing until 
postnatal day 21, which coincides with the period of neurite outgrowth (Mochizuki et 
al., 2003). In line with this, overexpression of Norbin in Neuro2A cells increases neurite 
number and length. Furthermore, Norbin expression is upregulated following 
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chemically-induced LTP, the process underlying neural plasticity and memory formation 
(Shinozaki et al., 1997). Additionally, conditional Norbin KO mice exhibit LTP deficits 
(later discussed in Section 1.6.4). Despite the discovery of Norbin’s role in group 1 mGluR 
signalling and neurite growth, there has been very little investigation of Norbin in 
schizophrenia.  
1.6 Group 1 mGluRs and their endogenous regulators in the pathology of 
schizophrenia 
1.6.1 Group 1 mGluRs-Evidence from knock-out and pharmacological models 
Knockout models support the involvement of group 1 mGluRs in the pathophysiology of 
schizophrenia. mGluR1 and mGluR5 KO mice exhibit sensorimotor deficits, a common 
phenotype observed in schizophrenia patients (Brody et al., 2003, 2004). In addition, 
hyperlocomotive deficits are also a common feature of schizophrenia rodent models, 
particularly when challenged with dopaminergic or glutamatergic agents such as 
amphetamine, phencyclidine, ketamine or MK-801. mGluR1 KO mice were first reported 
to exhibit reduced locomotor activity, owing to severe motor deficits observed in these 
mice, likely due to the role mGluR1 plays in cerebellar dysfunction (Conquet et al., 1994). 
However, a later study reported that whilst fine motor activity was disturbed in mGluR1 
KO mice, there was no change in baseline motor activity (Mao et al., 2001). Furthermore, 
mGluR1 KO mice showed increased amphetamine-induced hyperlocomotor activity 
compared to wild-type (WT) controls.  mGluR5 KO mice exhibit basal locomotor activity 
similar to WT controls (Chiamulera et al., 2001; Lu et al., 1997). Furthermore, 
administration of the dopamine reuptake inhibitor, cocaine, which induces a 
hyperlocomotive locomotor response in WT mice, has no effect in mGluR5 KOs, despite 
causing similar increases of dopamine levels in nucleus accumbens (Chiamulera et al., 
2001). This study not only demonstrated that mGluR5 plays a role in cocaine-induced 
behaviours, but highlights the important interaction between mGluR5, subcortical 
dopaminergic system and associated behaviours. In addition, Gray and colleagues 
(2009) reported mGluR5 KO mice exhibited increased hyperlocomotor activity in 
response to the NMDA receptor antagonist, MK-801, compared to WT controls, 
confirming the interaction that mGluR5 plays with the NMDA receptor. Collectively, 
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these studies implicate a role for mGluR5 in the function of dopaminergic and 
glutamatergic neurotransmission, key systems involved in the pathophysiology of 
schizophrenia.  
 
LTD and LTP are the molecular processes underlying synaptic plasticity and memory 
formation, and are believed to be disrupted in schizophrenia, at least in a subset of 
patients (Bhandari et al., 2016).  An array of studies show group 1 mGluRs play an 
integral role in synaptic plasticity and cognition, which has been clearly highlighted using 
mGluR1 and mGluR5 KO models. mGluR1 KO mice exhibit memory acquisition and 
retention deficits. Furthermore, these mice display reduced hippocampal LTP (Aiba et 
al., 1994; Bordi et al., 1997). mGluR5 KO mice exhibit impaired hippocampal dependent 
spatial learning performance in the Morris water maze and contextual fear conditioning 
tasks (Jia et al., 1998). In line with this, mGluR5 KO mice display NMDA-dependent LTP 
deficits in CA1 (Lu et al., 1997). Furthermore, intracerebroventricular injection of the 
mGluR5 antagonist, MPEP, dose-dependently inhibited LTP in the CA1 and dentate gyrus 
region of Wistar and Hooded Listar rats and impaired working and reference memory in 
Wistar rats in radial maze tasks (Manahan-Vaughan and Braunewell, 2005). mGluR5 has 
similarly shown to have a role in LTD, with LTD being abolished in mGluR5 KO mice 
(Huber et al., 2001). Furthermore, Purgert and colleagues, employed a pharmacological 
approach to activate cell surface and intracellular mGluR5, and identified that 
intracellular mGluR5 is responsible for mediating electrically- and chemically-induced 
LTD (Purgert et al., 2014). Induction of LTD via the group 1 mGluR agonist, (S)-3,5-
Dihydroxyphenylglycine (DHPG), was inhibited by the cell permeable mGluR5 
antagonist, 2-Methyl-6-(phenylethynyl)pyridine (MPEP), which is able to bind to mGluR5 
located not only on the cell surface but also on intracellular membranes such as the 
endoplasmic reticulum and nuclear membranes. However, application the non-
permeable mGluR5 antagonist (capable of only inbiting cell surface mGluR5), LY53, was 
unable to inhibit DHPG-induced LTD. This evidence indicates mGluR5’s role in LTD may 
be regulated by specific pools of mGluR5. Collectively, these studies demonstrate a role 
for group 1 mGluRs underlying synaptic plasticity and cognition; processed associated 
with the pathology of schizophrenia. 
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1.6.2 Group 1 mGluRs-Evidence from postmortem studies 
The investigation of group 1 mGluR ligand binding, mRNA and protein levels in 
schizophrenia subjects has previously been investigated across several postmortem 
cohorts and brain regions. A majority of gene expression studies have reported 
unaltered mGluR1 and mGluR5 transcript expression in the prefrontal cortex, 
hippocampus, thalamus, striatum and cerebellum of schizophrenia subjects (Table 1.2). 
However, there are also reports of altered expression, with Volk et al (2010) reporting a 
12% increase in mGluR1a transcript expression in the prefrontal cortex (Brodmann Area 
[BA] 9) of schizophrenia subjects and Fatemi and colleagues (2013) reporting reduced 
mGluR5 mRNA expression in the lateral cerebellum of schizophrenia subjects.  
 
Early studies examining mGluR1 and mGluR5 protein via immunoblot (under reducing 
conditions) in schizophrenia postmortem cohorts have largely reported no change in 
expression in the prefrontal cortex, caudate, putamen and nucleus accumbens (Table 
1.2). It is worth considering that these studies were limited by small sample sizes (<20 
samples). Despite this, a 10% increase of mGluR1a protein expression was reported in 
the prefrontal cortex of schizophrenia subjects (Gupta et al., 2005). Furthermore, a 
reduction of mGluR5 monomer protein has been observed in the lateral cerebellum and 
prefrontal cortex (BA9) of schizophrenia subjects, however no change in the dimeric 
form (Fatemi et al., 2013). Interestingly, our group previously investigated mGluR5 
protein expression in a schizophrenia cohort that had shown evidence of NMDA 
receptor dysfunction (Weickert et al., 2013). Whilst we found no change in mGluR5 
protein levels (monomeric band only) within the dorsolateral prefrontal cortex of 
schizophrenia subjects (Matosin et al., 2013), upon re-analysis of images and 
quantification of the dimeric band, we found overall and dimeric mGluR5 protein levels 
to be significantly increased within the same cohort. This highlights the importance of 
examining dimeric levels in particular, as these are believed to be the canonical form of 
mGluR5 receptors that reach the cell surface and interact with the NMDA receptor. 
Furthermore, as mGluRs exist in dimeric and monomeric forms, without quantification 
of both these bands, a true picture of mGluR protein expression cannot be reached. 
Recently, we also reported dimeric and monomeric mGluR5 protein levels to be 
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increased and mGluR1a levels to be decreased, in the CA1 region of the hippocampus, 
when examined under reducing conditions (Matosin et al., 2016a, 2015c). Further 
supporting the importance and implication of mGluR dimerisation, Corti et al (2007) 
reported that whilst total (dimer and monomer) and monomeric levels of mGluR3 were 
not altered in the prefrontal cortex (BA10), there was a significant reduction in mGluR3 
dimeric levels. There is emerging evidence of dimeric alterations of group 1 mGluRs in 
schizophrenia, however 1) no study has examined group 1 mGluR protein expression 
under non-reduced conditions, so are not able to measure total dimeric levels; and 2) it 
is unclear how widespread mGluR changes are in the brain.  
 
In line with the glutamatergic hypothesis, the prefrontal cortex and hippocampus are 
highly implicated in schizophrenia and are the focus of many postmortem investigations. 
The prefrontal cortex and hippocampus are involved in short and long-term cognitive 
function, both processes disrupted in schizophrenia pathology. These regions send 
excitatory glutamatergic projections to the ventral striatum, in particular the nucleus 
accumbens, another highly implicated region in schizophrenia (Britt et al., 2012). The 
nucleus accumbens is involved in reward and motivation, comprising of medium spiny 
neurons and dense with both dopaminergic and glutamatergic projections. It is thought 
that current antipsychotics, primarily exert their therapeutic effect through D2 receptors 
located on the medium spiny neurons (Deutch et al., 1992; Deutch and Cameron, 1992). 
It is this convergence of glutamatergic and dopaminergic projections on a γ-
Aminobutyric acid (GABA) interface that makes the nucleus accumbens a region of vast 
interest in schizophrenia pathology. Recently, evidence for glutamatergic pathology 
within the nucleus accumbens was supported by a series of postmortem studies from 
McCullum and Colleagues. McCollum and Roberts (2015) reported increased protein 
expression of the vesicle glutamate transporter, VGLUT2, in the nucleus accumbens of 
schizophrenia subjects. Further adding support to this glutamatergic dysfunction in the 
nucleus accumbens, they reported an increased number of asymmetric synapses, 
indicative of glutamatergic projections (McCollum et al., 2015). Whilst these studies are 
recent and were performed in small cohorts (n=13-20), they encourage further evidence 
characterising the glutamatergic system within the schizophrenia nucleus accumbens. 
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Table 1.2: Summary of mGluR1 and mGluR5 investigations in postmortem human brain tissue from schizophrenia patients. 




(PFC; (BA9, 10 and 
11)) 
In situ hybridisation: encoding 
for mGluR5 
Increased mGluR5 mRNA (28%) in layer III of BA11 in SCZ, but no 
change in BA9 or 10. 










In situ hybridisation: encoding 
for panmGluR5 




Thalamus In situ hybridisation:  
encoding for mGluR1 and 
mGluR5 
No change in both mGluR1 and mGluR5 mRNA. (Richardson-








Immunoblot:  analysis for 
mGluR1a and mGluR5 
(monomeric band-reducing 
conditions not stated) 
mGluR1a protein levels were increased in the PFC (10%) in SCZ. 
No difference of mGluR1a and mGluR5 in other regions 
examined. 




Dorsolateral PFC Receptor autoradiography: 





No significant difference between diagnosis and CT in [3H] MPEP 
binding or mGluR5 protein levels. 
 












[3H] MPEP binding to mGluR5 
 
No significant difference between diagnosis and CT. (Matosin et al., 
2013) 
  










Reduction in mGluR5 transcript expression in BP (23%). 
 
mGluR5 monomer was reduced in SCZ (32-53%) and BP (39-63%) 
compared to CT. 




















A reduction in mGluR5 mRNA in SCZ (51%) and MD (47%) 
compared to CT  
 
mGluR5 protein was reduced in SCZ (60-75%), BP (54-79%) and 










conditions): mGluR5 dimeric 
band 
mGluR5 mRNA levels were unaltered. 
 
Total mGluR5 protein levels were increased (22%) in SCZ (dimer: -
54%).  




Hippocampus (CA1) Immunoblot (reducing 
conditions): mGluR5 dimeric 
and monomeric bands 
Total mGluR5 protein levels were increased (42%) in SCZ. 
 
Increase of mGluR5 dimer (52%) and monomer (25%) bands. 




Hippocampus (CA1) Immunoblot (reducing 
conditions): mGluR1a dimeric 
and monomeric bands 
Total mGluR1α protein levels were reduced (-32%) in SCZ. 
 
Reduction in mGluR1a dimer (-66%) and monomer (-67%).  
(Matosin et al., 
2016a) 
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1.6.3 Homer1  
Homer1 KO mice display schizophrenia-like behaviours, including increased locomotive 
response when challenged with acute administration of MK-801 and methamphetamine 
(Szumlinski et al., 2005). In addition, Homer1 KO mice display anxiety-like behaviour and 
behavioural despair, as well as working and spatial memory deficits, which are mediated 
by cortical and hippocampal regions, respectively (Gerstein et al., 2012; Szumlinski et 
al., 2005). Furthermore, Homer1 KO mice exhibit sensorimotor impairments, which can 
be attenuated with the typical antipsychotic, haloperidol (Szumlinski et al., 2005). Whilst 
these studies implicate Homer1’s involvement in behavioural impairments associated 
with neuropsychiatric disorders, they do not discriminate which Homer1 isoforms may 
underlie these behaviours. However, the use of adeno-associated virus (AAV) to induce 
expression of specific Homer1 isoforms in Homer1 KO models has provided a tool to 
elucidate this issue. Homer1 KO mice infused with the AAV Homer1 long isoform in the 
prefrontal cortex, reversed stress related learning impairments, observed by deletion of 
Homer1. In regards to the short Homer1 isoform, upregulation of Homer1a has been 
observed following psychotomimetic drug exposure, the introduction to novel 
environments, fear conditioning and avoidance learning tasks (Cochran et al., 2002; 
Fujiyama et al., 2003; Igaz et al., 2004; Vazdarjanova et al., 2002). Collectively, this 
suggests that the short form, Homer1a, may be involved in adaptive behaviours 
following stress. Furthermore, AAV infusion of Homer1c, but not Homer1a, in the 
prefrontal cortex of Homer1 KO mice, reversed working memory and sensorimotor 
deficits (Lominac et al., 2005). In addition, Homer1 KO mice exhibit increased 
extracellular glutamate in the prefrontal cortex, which was reversed by AAV infusion of 
Homer1c (Lominac et al., 2005). This suggests that Homer1c plays an integral role in 
cognitive and sensorimotor processing, which may be associated with frontal cortical 
glutamate levels. In addition, it appears Homer1c may also play a role in hippocampal 
dependent memory, as AAV infusion of Homer1c in the hippocampus has demonstrated 
to restore spatial memory and LTP deficits in Homer1 KO mice (Gerstein et al., 2012). 
Moreover, this effect was abolished by mGluR5, but not mGluR1, antagonism indicating 
Homer1c facilitates synaptic plasticity effects via its interaction with mGluR5 (Gerstein 
et al., 2012). Collectively, these findings in rodents highlight the distinct role Homer1 
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isoforms play in behaviours associated with neuropsychiatric disorders and therefore 
may play a role in the pathology of these disorders. 
A genetic study examining HOMER1, provided the first evidence implicating Homer1 in 
schizophrenia. Norton et al., (2003) identified several single nucleotide polymorphisms 
were associated with schizophrenia and other neuropsychiatric disorders. In addition, 
Spellmann and colleagues (2011) identified HOMER1 polymorphisms are associated 
with symptom severity and antipsychotic response. Furthermore, antipsychotics have 
demonstrated to regulate HOMER1 gene expression in rodent models (discussed later 
in Section 1.7). Despite these findings, there has been limited investigation of Homer1 
in postmortem cohorts. Engmann et al., (2011) reported reduced Homer protein 
expression in the PFC and hippocampus of a postmortem schizophrenia cohort, however 
the antibody employed in this study was not specific for any Homer isoform. We recently 
reported an increase in Homer1a and a decrease in Homer1b/c protein expression in 
the CA1 of a schizophrenia postmortem cohort, in which we also showed concomitant 
mGluR1 and mGluR5 alterations (Matosin et al., 2015c, 2016b). Whether the alterations 
in Homer1 in schizophrenia extends to other brain regions is yet to be investigated. 
1.6.4 Norbin 
While constitutive Norbin KO is lethal (Mochizuki et al., 2003), conditional Norbin KO 
mice have previously been generated from the Greengard lab (Wang et al., 2009). In 
these mice Norbin protein is deleted specifically from the postnatal forebrain, leaving 
mid- and hind-brain mGluR5 intact. Conditional Norbin KO mice exhibit reduced cell 
surface expression of mGluR5, however overall expression appears unaltered, indicating 
Norbin is responsible for trafficking mGluR5 to the cell surface (Wang et al., 2009). 
Norbin KO mice display many behaviours reminiscent of neuropsychiatric models, 
including pre-pulse inhibition abnormalities and increased hyperlocomotive response to 
MK-801 (Wang et al., 2009). Furthermore, they also demonstrate depressive like 
behaviours, with reports of reduced mobility times in forced swim and tail suspension 
tests (Wang et al., 2015). Further investigation also show these mice exhibit many 
neurochemical abnormalities associated with schizophrenia and depression. Norbin KO 
mice exhibit reduced DHPG (group 1 mGluR agonist)-induced LTP and LTD in 
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hippocampal Schaffer collateral-CA1 synapses, signifying synaptic plasticity deficits in 
these mice (Wang et al., 2009). In addition, Norbin ablation reduces adult neurogenesis 
in the subgranular zone, reducing the proliferation of neural stem cells. Further analysis 
showed that these impairments in adult neurogenesis were through non-autonomous 
effects as Norbin expression was extremely low in neural stem and precursor cells (Wang 
et al., 2015). Although our knowledge about Norbin and its role in neuropsychiatric 
disorders is still within its infancy, Norbin provides a novel candidate molecule of 
interest, which warrants further investigation. 
 
The work investigating pathological changes to Norbin in psychiatric postmortem 
cohorts is still in its infancy. However, Mudge and colleagues reported reduced Norbin 
mRNA levels in the cerebellar cortex of schizophrenia subjects (Mudge et al., 2008). 
Furthermore, we recently reported increased Norbin protein levels in the CA1 region of 
the hippocampus (Matosin et al., 2015c) and reductions in the dorsolateral prefrontal 
cortex (BA46) of schizophrenia subjects (Matosin et al., 2015a), indicating unique brain 
region effects. Contrary to this, Martins-de-Souza et al., (2012) showed a modest 
increase of Norbin protein levels within the dorsolateral prefrontal cortex (BA9) of major 
depression subjects with psychosis compared to those without psychosis. This evidence 
implicating Norbin in the pathology of schizophrenia and depression, may consequently 
contribute to changes in localisation and signalling of group 1 mGluRs.  
1.7 Effect of Current Antipsychotic Drugs on Group 1 mGluR  
Antipsychotic drugs are widely used in the treatment of schizophrenia, particularly the 
positive symptoms, with all current antipsychotics sharing a strong affinity for the 
dopamine D2 receptor (Kapur and Mamo, 2003). First generation antipsychotics such as 
haloperidol are primarily D2 receptor antagonists, whilst second generation 
antipsychotics such as clozapine, olanzapine and sertindole have additional affinity for 
other neurotransmitter systems such as the serotonergic, muscarinic and histaminergic 
systems (Mauri et al., 2014). First and second generation antipsychotics primarily treat 
only positive symptoms. Furthermore, chronic use of these compounds is accompanied 
by an array of side effects such as extrapyramidal symptoms, agranulocytosis, weight 
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gain, type 2 diabetes mellitus and hypercholesterolaemia (Henderson et al., 2000). More 
recently, a third generation of antipsychotics was developed, most notably aripiprazole, 
which has shown favourable efficacy for the treatment of schizophrenia and reduced 
side-effects (Di Sciascio and Riva, 2015). Whilst aripiprazole is a D2 receptor partial 
agonist (Shapiro et al., 2003), the mechanisms underlying its therapeutic profile appear 
complex and largely unknown. There is particular benefit in attempting to understand 
the neurochemical changes antipsychotics may induce for several reasons: 1. To offer a 
comparison against findings from postmortem studies and discriminate between 
pathological changes and changes which could be induced by antipsychotics; 2. Identify 
antipsychotics that may target certain neurotransmitter systems that could profit a sub 
group of patients; 3. Identify potential “off target” side effector systems and 4. Identify 
novel therapeutic targets. 
 
Despite the fact that current antipsychotics do not have affinity for the range of 
glutamatergic receptors, evidence indicates antipsychotics indirectly modulate the 
glutamatergic system. Several studies demonstrate antipsychotic drugs, including 
haloperidol and aripiprazole, can alter the ligand binding, mRNA and protein expression 
of glutamatergic ionotropic receptors, in particular AMPA and NMDA receptors, within 
the nucleus accumbens (Fitzgerald et al., 1995; Healy and Meador-Woodruff, 1997; Pan 
et al., 2016; Schmitt et al., 2003; Spurney et al., 1999). Studies investigating the effect 
of antipsychotics on glutamatergic receptors have largely focused on ionotropic 
receptors, limited studies have investigated the influence of antipsychotics on group 1 
mGluRs. Volk et al., (2010) reported chronic (17-27 months) treatment with either 
haloperidol (2.0-4.0 mg/day) or olanzapine (1.1-2.2 mg/day) had no effect on mGluR1a 
mRNA in the prefrontal cortex of Macaque monkeys. Similarly, a rodent study did not 
observe a change in mGluR1 or mGluR5 transcripts in the frontal cortex, striatum or 
hippocampus following antipsychotic treatment (3 weeks; haloperidol 1 mg/kg; 
clozapine 10 mg/kg and olanzapine 2 mg/kg) (Tascedda et al., 2001). This is in line with 
studies conducted in our laboratory, which have also reported unchanged mGluR5 
protein expression within the prefrontal cortex and hippocampus of rodents chronically 
treated with haloperidol (0.3 mg/kg dose; 8, 16 and 36 days) or olanzapine (3 mg/kg; 8, 
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16 and 36 days duration) (Matosin et al., 2015a, 2015c). Furthermore, we did not detect 
a change in [3H] MPEP binding to mGluR5 in the rodent prefrontal cortex, hippocampus 
or striatum following haloperidol or olanzapine treatment (Matosin et al., 2013). Whilst 
the aforementioned studies examined the entire regional structures, it appears there 
may be sub-regional differences, particularly within the striatum. Iasevoli et al., (2010) 
reported increased mGluR5 mRNA expression in the dorsal striatum (putamen) 
following chronic treatment with haloperidol or sertindole, however, this did not extend 
to the ventral striatum (nucleus accumbens). There appears to be little evidence to date 
suggesting group 1 mGluR mRNA or protein expression is influenced following 
administration of first and second generation antipsychotics. However, protein 
expression studies have only examined the monomeric form of mGluR5 and not the 
dimeric form, which is now known to be the functional form required for agonist-
activation and downstream signalling (El Moustaine et al., 2012). Furthermore, group 1 
mGluR protein expression has yet to be examined following administration with a third 
generation antipsychotic, such as aripiprazole, which has superior long-term efficacy 
and more favourable adverse effect profile, than haloperidol (Kasper et al., 2003; Stip 
and Tourjman, 2010). Understanding the neurochemical changes associated with 
advantageous treatments such as aripiprazole, particularly changes core its therapeutic 
efficacy can improve future drug design. 
 
Studies investigating proteins that endogenously regulate group 1 mGluRs, particularly 
Homer1, have shown to be influenced by antipsychotic treatment. A large body of work 
from de Bartolomeis and colleagues has revealed the influence antipsychotics can have 
on Homer1 expression, in particular the short form, Homer1a (Ambesi-Impiombato et 
al., 2007a; de Bartolomeis et al., 2002a; Iasevoli et al., 2010b, 2011a; Tomasetti et al., 
2007). Interestingly, evidence from this work indicates antipsychotic D2 receptor 
blockade is positively associated with Homer1a expression, specifically in the striatum 
(Ambesi-Impiombato et al., 2007; de Bartolomeis et al., 2016). de Bartolomeis and 
colleagues (2015) reported acute treatment with the typical antipsychotic, haloperidol, 
induces a gradual dose-dependent increase of Homer1a mRNA expression in the 
striatum. Furthermore, acute treatment with 2nd and 3rd generation antipsychotics 
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olanzapine, clozapine, asenapine, ziprasidone and aripiprazole, have also shown to 
increase Homer1a mRNA in the striatum (de Bartolomeis et al., 2002, 2015b; Iasevoli et 
al., 2010b, 2010a; Polese et al., 2002; Tomasetti et al., 2007).  However, sertindole, a 
second generation antipsychotic did not show an effect on Homer1a expression in the 
striatum, which may highlight that various antipsychotics preferentially induce Homer1a 
expression (Iasevoli et al., 2010b). In addition, antipsychotics may induce Homer1a 
expression in a brain region specific manner. In fact, acute treatment with haloperidol, 
olanzapine or clozapine has shown to have no effect on hippocampal Homer1a 
expression, however has shown to increase Homer1a expression in cortical and striatal 
regions (Iasevoli et al., 2009, 2010b).  The striatum, in particular the nucleus accumbens, 
is a region of great interest not only because it is thought to be the “action” site of 
antipsychotics (due to its high concentration of D2 receptors), but it also contains an 
abundance of glutamatergic terminals, where Homer1 is localised. Collectively, studies 
suggest acute treatment with 1st, 2nd and even 3rd generation antipsychotic drugs can 
increase Homer1a mRNA in the nucleus accumbens, however, Homer1b/c levels are 
largely reported to be unchanged. Considering the role of Homer1a, this suggests that 
acute antipsychotic treatment may alter mGluR1/5 signalling in the nucleus accumbens, 
uncoupling its attachment to IP3 and shifting its signalling towards G-protein 
independent pathways. However, it should be noted that these previous studies have 
focused on mRNA levels, which may not reflect protein levels (Greenbaum et al., 2003). 
Future studies should examine the protein expression of these endogenous modulators 
and their interaction with group 1 mGluRs to gain a deeper insight into their potential 
therapeutic significance.  
 
While a growing body of evidence indicates acute antipsychotic treatment influences 
Homer1 expression, patients in the clinic undergo chronic treatment, therefore, 
appropriately modelling and understanding the chronic effect of these antipsychotics 
may provide more relevant information to the clinical situation. Furthermore, studies 
have reported differential mRNA and protein responses to short- and long-term 
antipsychotic administration (Deng et al., 2015). Such studies can identify if acute effects 
are preserved or if chronic treatment may cause neuro-adaptations that are key to their 
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efficacy. Furthermore, considering Homer1 plays a key role in synaptic plasticity, insights 
into the long-term effect of antipsychotics may identify the therapeutic mechanism of 
antipsychotics. There have been several studies investigating this in regards to Homer1 
within the nucleus accumbens. However, reports have been inconsistent reporting no 
change and increases of Homer1a and Homer1b/c mRNA transcripts within identical 
models (Ambesi-Impiombato et al., 2007; Iasevoli et al., 2010b, 2011; Tomasetti et al., 
2007). Whilst it is unclear why there are inconsistencies within identical models, further 
studies examining this area may highlight the role Homer1 plays in antipsychotic-
induced synaptic plasticity.  
 
When modelling the antipsychotic drug exposure in rodent models, several 
considerations should be noted to ensure clinical relevance. It is difficult to make direct 
translations between human and rodents based on body weight as drug absorption and 
metabolism differ between species. However, D2 receptor occupancy is a widely 
accepted parameter to translate dosage (Kapur, 1998; Kapur et al., 2003). In regards to 
drug delivery, several drug delivery methods have been used in previous studies, 
including mini-pumps, intraperitoneal or subcutaneous injection, oral gavage and oral 
self-administration via drinking water, however these methods have limitations that 
must be considered. As such, studies thus far investigating the effect of chronic 
antipsychotic treatment on Homer1 expression have employed a daily intraperitoneal 
injection paradigm (Ambesi-Impiombato et al., 2007; de Bartolomeis et al., 2002, 2013, 
2015b; Iasevoli et al., 2010a, 2011; Spellmann et al., 2011; Tomasetti et al., 2007). 
Injections and oral gavage require regular handling and place stress on the rodent, which 
may place limitations on results, in particular on Homer1, which is known to be 
influenced by stress (Shui et al., 2015; Wagner et al., 2015). Furthermore, the half-life of 
antipsychotics is 4-6 times faster than humans, therefore, rodents must be dosed higher 
and/or more frequently to achieve similar D2 receptor occupancy levels to humans 
(Kapur et al., 2003). Whilst delivery via drinking water may overcome these problems, 
water intake may fluctuate, consequently causing maintenance of a steady dose 
problematic. Furthermore, several antipsychotics are not readily water-soluble. 
Similarly, antipsychotic delivery through mini-pumps can lead to degradation of the 
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compound. However, a number of studies have employed oral self-administration 
through a delivery of the antipsychotic encased in a pleasant tasting treat such as peanut 
butter or cookie-dough (Han et al., 2008; Huang-Brown and Guhad, 2002). Not only does 
oral administration better replicate the clinical scenario, it avoids invasive surgeries, 
unnecessary handling and stress associated with injections and/or oral gavage. 
Furthermore, antipsychotics can be given at numerous times throughout the day to keep 
D2 receptor occupancy levels stable. Prospective studies investigating the effects of 
chronic antipsychotic treatment on Homer1 expression may benefit from using such a 
treatment paradigm. 
1.8 mGluR5 positive allosteric modulation as a therapeutic target for 
schizophrenia 
There is a pressing need to develop novel therapeutic approaches for treating 
schizophrenia that not only avoid the debilitating side effects but also, effectively treat 
all symptoms domains of the disorder. mGluR5 was originally identified as a therapeutic 
target for schizophrenia due to its ability to modulate NMDA receptor deficits (Kinney 
et al., 2005), which are thought to be associated with schizophrenia, at least in a subset 
of schizophrenia patients. However, due to the distribution and dynamic signalling 
pathways of mGluR5 (for review see Matosin and Newell, 2013), several other potential 
therapeutic mechanisms are thought to be possible (Rook et al., 2015). Pharmacological 
stimulation of mGluR5 has shown promising potential to improve cognitive behaviours 
(Ayala et al., 2009; Uslaner et al., 2009; Clifton et al., 2013). While mGluR5 is considered 
a novel therapeutic target, agonist stimulation of mGluR5 in rodents has been reported 
to cause seizures and rapid receptor desensitisation (Wong et al., 2005). However, in 
the last decade a new class of mGluR5 stimulators, in the form of positive allosteric 
modulator (PAM) compounds, have been synthesised to specifically target mGluR5 
(O’Brien et al., 2003). 
 
mGluR5 PAMs are a class of compound which bind within the transmembrane region of 
mGluR5 and cause a conformational change to the receptor, generally without exerting 
an intracellular signalling response on their own, in contrast to a typical orthosteric 
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agonist (Vinson and Conn, 2012). However, when a PAM is co-bound with an mGluR5 
endogenous orthosteric ligand (i.e.  glutamate), the activity of mGluR5 is heightened and 
the PAM further potentiates downstream signalling pathways (Kinney et al., 2005). Since 
the first development of mGluR5 PAMs over a decade ago, there has been a surge in the 
number of developed and tested compounds. mGluR5 PAMs which have been examined 
in vivo include ADX-47273 (developed by Addex Therapeutics), CDPPB (3-Cyano-N-(1,3-
diphenyl-1H-pyrazol-5-yl)benzamide) (developed by Merck) and VU-analogues 
(developed by the Vanderbilt Centre for Neuroscience Drug Discovery).  
 
mGluR5 PAMs have provided a new therapeutic strategy to attenuate several 
schizophrenia-like behaviours in animal models. A variety of mGluR5 PAMs have shown 
success in reversing a wide range of positive- and negative-like behaviours induced via 
NMDA receptor antagonist or dopaminergic agonist agents, including hyperlocomotion, 
pre-pulse inhibition and sucrose preference deficits (for detailed review see Matosin and 
Newell, 2013). However, one of the most promising features of mGluR5 PAMs is their 
ability to offset social, spatial and working memory deficits, a property not associated 
with current antipsychotics. mGluR5 PAMs have demonstrated efficacy to attenuate 
cognitive deficits including in the Morris water maze, social novelty discrimination, set 
shifting performance, novel object recognition and conditioned avoidance tasks in 
various animal models of schizophrenia (Ayala et al., 2009; Balschun et al., 2006; Chan 
et al., 2008; Darrah et al., 2008; Horio et al., 2013; Liu et al., 2008; Stefani and 
Moghaddam, 2010; Uslaner et al., 2009). Collectively, the preclinical evidence for 
mGluR5 PAMs is promising for treating a wide range of behaviours associated with 
schizophrenia. Recently mGluR5 PAMs have been further investigated to treat other 
neuropsychiatric and neurological disorders as well. In particular, the mGluR5 PAM, 
CDPPB has demonstrated potential in the treatment of autism (Won et al., 2012), Rett 
syndrome (Gogliotti et al., 2016), post-traumatic stress disorder (Sethna and Wang, 
2014), Huntington’s disease (Doria et al., 2013), ethanol and cocaine seeking behaviour 
(Cleva et al., 2011). Whilst these studies investigating CDPPB are in early preclinical 
stages, the evidence is favourable and encourages further investigation. 
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1.8.1 Therapeutic potential of CDPPB 
CDPPB has been the most extensively investigated mGluR5 PAM to date, demonstrating 
antipsychotic and pro-cognitive effects in schizophrenia rodent models. Kinney et al, 
(2005) showed CDPPB has low oral availability (F=2.9%) when delivered in 1% 
methycellulose. However, intravenous injection CDPPB (2 mg/kg; dimethyl sulfoxide 
(DMSO)) in Sprague-Dawley rats has a plasma half-life of 4.4 hrs, with a volume 
distribution of 3.5 l/kg and clearance of 25.1 ml/min/kg (Kinney 2005). Furthermore, 
CDPPB is brain penetrable with a brain/plasma ratio of 1.7 (Kinney 2005), indicating it is 
a suitable compound for in vivo investigation.  
 
Similar to many of the other PAMs, CDPPB competes with binding of the MPEP binding 
site (Kinney et al., 2005). CDPPB does not increase agonist binding affinity, nor does 
glutamate affect CDPPB binding at the MPEP binding site (Kinney et al., 2005). Rather, 
CDPPB exerts its effect through increasing the functional potency of the mGluR5 
orthosteric agonist. One unexpected property of CDPPB is its ability to activate mGluR5 
in the absence of an agonist (Kinney et al., 2005; Noetzel et al., 2012). Therefore, CDPPB 
has been termed an ago-PAM, rather than a “pure” PAM. However, it has been 
demonstrated in HEK293 cells that the agonist properties of ago-PAMs are dependent 
on mGluR5 expression levels, with CDPPB showing agonist activity in the presence of 
high levels of mGluR5. However all ago-PAMs, including CDPPB, have shown no agonist 
activity in primary cells, including cortical astrocytes and cultured neurons from the 
subthalamic nucleus; this suggests mGluR5 PAMs, such as CDPPB, may exhibit agonist 
activity in recombinant cell lines, however does not reflect or predict agonist activity in 
native systems (Noetzel et al., 2012).  
 
Acute CDPPB treatment has shown antipsychotic-effects in attenuating NMDA receptor 
antagonist- and amphetamine-induced hyperlocomotion and pre-pulse inhibition 
deficits (Fowler et al., 2011, 2013; Kinney et al., 2005a). In addition, CDPPB was shown 
to attenuate MK-801-induced anhedonia and immobility time in the sucrose preference 
and forced swim tests, behaviours used to assess negative-like symptoms (Vardigan et 
al., 2010; Wierońska et al., 2015). However, the most promising aspect of mGluR5 PAMs, 
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including CDPPB are their pro-cognitive effects. CDPPB was shown to potentiate both 
LTP and LTD within the Schaffer collateral-CA1 synapse of hippocampal slices (Ayala et 
al., 2009). This is further supported by CDPPB’s ability to enhance rodent performance 
in the Morris water maze (Ayala et al., 2009). Furthermore, acute CDPPB administration 
has demonstrated to attenuate NMDA receptor antagonist-induced deficits in novel 
object recognition and cognitive flexibility tasks (Lacrosse et al., 2015; Stefani and 
Moghaddam, 2010; Uslaner et al., 2009).  
 
Collectively, studies investigating acute CDPPB treatment report great efficacy in 
attenuating schizophrenia-like behaviours (Table 1.3). However, in an attempt to mimic 
a more clinically relevant situation, studies have focused on investigating the effects of 
chronic CDPPB administration. The first of these studies demonstrated seven-day CDPPB 
treatment (30 mg/kg; i.p) showed the ability to reduce amphetamine-induced 
hyperlocomotion in adult rats (Parmentier-Batteur et al., 2012). This effect was to the 
same degree as rodents treated acutely with CDPPB, indicating tolerance is not 
developed following chronic CDPPB treatment, at least in this paradigm. In addition, this 
study also included a withdrawal group, which received CDPPB for six days, yet did not 
receive CDPPB treatment on the day of the amphetamine challenge. Rodents in the 
withdrawal group did not display any efficacy in attenuating amphetamine-induced 
hyperlocomotion, suggesting the effects of CDPPB are reversible following even a brief 
washout period (Parmentier-Batteur et al., 2012). Horio and colleagues (Horio et al., 
2013) examined both the acute and chronic effects of CDPPB (10 mg/kg; i.p) in 
ameliorating PCP-induced (10 mg/kg for consecutive 10 days) cognitive deficits in adult 
mice. Chronic (14 day), but not acute, CDPPB treatment was able to attenuate PCP-
induced deficits in novel object recognition (Horio et al., 2013). Subsequently, Clifton 
and colleagues brought attention to the idea that early mGluR5 PAM intervention may 
be able to prevent schizophrenia-like behaviours.  They were able to demonstrate 
chronic CDPPB (10 mg/kg; i.p; 12 days) treatment at adolescence (PN35-46) was able to 
attenuate social cognitive deficits induced in the perinatal PCP model of schizophrenia 
(Clifton et al., 2013). Furthermore, these effects were observed in adulthood, six weeks 
after withdrawal from treatment. This supports the possibility that early intervention, 
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targeting mGluR5, may be a future therapeutic avenue, however this is the only study 
to investigate adolescent mGluR5 PAM treatment and therefore further investigation is 
required. 
 
Despite CDPPB’s promising ability to treat schizophrenia-like symptoms in rodent 
models, there is still little known in regards to CDPPB’s effect at a molecular, cellular and 
circuitry level. The major attraction of mGluR5 PAMs, including CDPPB, is their ability to 
counteract NMDA receptor dysfunction. In line with this, CDPPB (3 and 10 mg/kg; i.p) 
was demonstrated to attenuate spontaneous activity of medial prefrontal cortex 
neurons, induced via the NMDA receptor antagonist, MK-801, supporting the potential 
of CDPPB to treat NMDA receptor deficits (Lecourtier et al., 2007). Furthermore, Chen 
et al., (2011) demonstrated CDPPB was able to restore the reduced field potentials 
induced via the NMDA receptor antagonists, ketamine (non-competitive) and D-APV 
(competitive), in hippocampal slices. This was mediated via CDPPB’s ability to modulate 
the PKC pathway, as application with the PKC inhibitor, chelerythrine chloride, blocked 
this effect. PKC activation was shown to phosphorylate NMDA receptors as well as 
activate CAMKII and CREB pathways, which are downstream of the PKC pathway 
(Benquet et al., 2002; Jia et al., 1998). Uslaner et al., (2009) demonstrated acute CDPPB 
treatment (3, 10 and 30 mg/kg; i.p) increased synaptic NR1 (ser896) and NR2B (1303) 
phosphorylation in the frontal cortex and hippocampus and increase phosphorylation of 
the AMPA GluA1 subunit (ser845) at various doses. Whilst these results support a role 
of CDPPB to upregulate NMDA and AMPA receptor activity, the study showed dose- and 
brain region- dependent responses. In the frontal cortex, phosphorylation of NR1, NR2B 
and GluA1 showed an inverted U-dose dependent effect, whilst in the hippocampus a 
linear dose-effect was observed, indicating CDPPB may exert brain-region specific 
differences. In support of these brain region specific differences, Parmentier-Batteur et 
al., (2012) reported that acute administration of CDPPB (30 mg/kg) in adult rats caused 
increased phosphorylation of NR1 and NR2B (ser1303) in the frontal cortex and 
striatum; this effect was still observed in the striatum following 7-day CDPPB treatment, 
but was absent in the frontal cortex. Whilst mGluR5 PAMs have shown promising 
behavioural potential, knowledge of their neurochemical effects is still limited. 
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Furthermore, studies examining the neurochemical effects of CDPPB have been 
performed in adult rats. In light of the notion that adolescent CDPPB treatment may be 
a potential therapeutic strategy, it is imperative to investigate if adolescent CDPPB 
treatment causes similar neurochemical changes, as reported in adult rats and if these 
changes are long-term. A deeper understanding of the neurochemical effect of CDPPB 
may enhance the development of not only CDPPB, but also mGluR5 as a treatment for 
schizophrenia and potentially other neuropsychiatric disorders.  
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Table 1.3: Summary of preclinical studies assessing the behavioural and neurochemical efficacy of CDPPB in rodents. 




Open field test: 
 CDPPB (1, 3 and 30 mg/kg s.c.) 20 mins prior to amphetamine (1 
mg/kg s.c). 
 
 CDPPB dose-dependently decreased amphetamine-induced hyperlocomotion 
activity. 
Kinney et al, 2005 
 
Pre-pulse inhibition: 









Morris water maze: 
 CDPPB (10 mg/kg) 20 mins prior to testing during  seven-day training. 
 
 CDPPB enhanced performance in Morris water maze. 
Alaya et al., 2009 
Adult male Wistar 
Hannover  
Novel Object Recognition: 
 CDPPB (0, 10 and 30 mg/kg; i.p) administration in unimpaired rats. 
 
 CDPPB (0, 10 and 30 mg/kg; i.p) immediately prior to MK-801 (0.3 
mg/kg; i.p) . 
 
 CDPPB (10mg/kg) enhanced novel object recognition performance. 
 
 CDPPB (3mg/kg) attenuated MK-801-induced  recognition memory deficits. 
Uslaner et al, 2009 
Adult male Wistar-
Hannover rats 
Sucrose preference test: 
 CDPPB (3 mg/kg i.p), 30mins prior to MK-801 treatment (0.3mg/kg). 
 
 CDPPB treatment attenuated MK-801 induced anhedonic behaviour similar to 
clozapine and D-serine. 




Set shifting task: 
 CDPPB (10 or 30 mg/kg; i.p), 20 mins following MK-801 (0.1 mg/ml) 
treatment. 
 






Inhibitory avoidance, open field test and taste aversion tests: 









 CDPPB (3 mg/kg) treatment attenuated MK-801-induced latencies. 
 
Open Field test:  
 CDPPB (3 mg/kg) attenuated MK-801-induced hyperlocomotion. 
 
Conditioned taste aversion:  




Fowler et al. 2011 
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Male ICR mice (6 
weeks old) 
Morris water maze: 
PCP (10 mg/kg) from experimental days 1-5 and 8-12 
 Acute CDPPB (10mg/kg; i.p) 3 days following last PCP injection 
(experimental day 15). 
 
 Chronic CDPPB (1 or 10mg/kg; i.p) 3 days following last PCP injection 
(experimental day 15) for 14 consecutive days. 
 
 
 CDPPB did not attenuate PCP-induced recognition memory deficits. 
Horio et al., 2012 
 
 CDPPB (10mg/kg) attenuated PCP-induced recognition memory deficits. 
Adult Wistar rats Amphetamine-induced hyperlocomotion: 
 Acute or daily CDPPB (30 mg/kg; i.p) treatment for either 6 or 7 days 
prior to amphetamine (0.75mg/kg)  challenge. 
 
 Acute and 7-day CDPPB treatment group attenuated amphetamine-induced 
hyperlocomotion. 
Parmentier-Batteur 
et al., 2012 
Male Wistar rats Social novelty discrimination: 
Parametric deficits protocol: 
 CDPPB (0.16, 2.5, 10 and 40 mg/kg; i.p). 
 
Parametric deficits protocol: 
 CDPPB was infused bilaterally in the frontal cortex (0.63, 2.5, 10 
ug/side) or striatum (2.5 ug/side). 
 
Pharmacological deficit protocol: 
 CDPPB (10 mg/kg; i.p) 45 mins following MK-801 (0.08 mg/kg; s.c).  
 
Perinatal PCP model: PCP (10 mg/kg; s.c) injections on PN7, 9 and 11. 
 Adolescent (PN35-46) CDPPB (10 mg/kg/day; s.c) 




 CDPPB (2.5 and 10 mg/kg) improved social novelty discrimination performance. 
 
 
 CDPPB (2.5 ug/side) infusion within frontal cortex improved ocial novelty 
discrimination performance. No effect was observed in striatum. 
 
 
 CDPPB attenuated MK-801 induced social novel discrimination deficits. 
 
 
 Adolescent CDPPB prevented perinatal PCP-induced social novelty 
discrimination deficits when tested at 8 weeks and 13 weeks. 
 Adult CDPPB treatment had no effect on perinatal PCP-induced social novelty 
discrimination deficits when tested at 13 weeks. 
Clifton et al., 2013 





Adult male Sprague 
Dawley rats 
Barnes maze task: 




 CDPPB (10 or 30 mg/kg; s.c) 20 mins prior training for 5 days. 
 




 CDPPB (30 mg/kg) enhanced T-maze acquisition performance. 




Set shifting task: 
 CDPPB (20 mg/kg) 30mins prior to MK-801 (0.06 mg/kg). 
 
 CDPPB treatment prevented MK-801 induced set-shifting deficits. 
LaCrrosse et al., 
2014 
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Adult male Wistar 
rats  
Forced swim test: 
 MK-801 (0.4 mg/kg, i.p) for 13 days, with a 1-day washout period prior 
to forced swim test. CDPPB (0.1, 0.5, 1 and 2 mg/kg) was administered 
30 mins before forced swim. 
 
DOI-induced head twitches: 
 CDPPB (1, 5 and 10 mg/kg) was administered was 30 mins prior to DOI 
(2.5 mg/kg; i.p). 
 
Haloperidol induced catalepsy: 
 CDPPB (0.25, 0.5, 1 and 2 mg/kg) was administered was 30 mins prior 
to haloperidol (0.1 mg/kg) 
 
Novel object recognition task: 
 CDPPB (1, 2 and 5 mg/kg) was administered 30 mins prior to MK-801 
administration. 
 













 CDPPB (2 and 5 mg/kg) attenuated MK-801-induced novel object recognition 
deficits. 




Paired associated learning: 
 CDPPB (3, 10 and 30 mg/kg; i.p) was administered 5 mins prior to MK-
801 (0.15 mg/kg; i.p) administration. 
 
 CDPPB did not attenuate MK-801-induced learning deficits. 







 CDPPB (10 mg/kg; i.p) 30 mins prior to MK-801 (0.1 mg/kg; i.p) 
administration. 
Microdialysis: 
 CDPPB (10 mg/kg; i.p) 20 mins prior to MK-801 (0.1mg/kg; i.p) 
administration. 




 CDPPB treatment did not reverse MK-801 induced dopamine release in the 
medial prefrontal cortex and nucleus accumbens. 
Lecourtier et al., 
2007 
Adult male Wistar 
Hannover 
Unimpaired rats administered CDPPB (0, 10 and 30 mg/kg; i.p) and 
euthanised 1 hr after CDPPB treatment. 
 
 CDPPB (10 and 30mg/kg) increased synaptic expression and phosphorylation of 
pNR1 (ser896) and pNR2B (ser1303) in the hippocampus. 
 CDPPB (3 and 10mg/kg) increased synaptic pNR1 and pNR2B in frontal cortex. 
 CDPPB (3,10 and 30 mg/kg) increased pαCAMK11 (Thr286) expression in the 
hippocampus. 
 CDPPB (10mg/kg) increased pCREB in hippocampus and PFC. 
 CDPPB (3 and 10 mg/kg) increased pGluA1 in hippocampus and PFC. 
Uslaner et al, 2009 
Adult Wistar rats Acute or daily CDPPB (30 mg/kg; i.p) treatment for either 6 or 7 days 
prior to amphetamine (0.75mg/kg) challenge. 
 CDPPB treatment for 7-days reduced [3H] bMax and kD in PFC, but not striatum 
 Acute and 7-day CDPPB treatment increased pNR1 (ser896), pNR2B (ser1303) 
in striatum and frontal cortex. 
Parmentier-Batteur 
et al., 2012 
Abbreviation: s.c, subcutaneous; i.p, intraperitoneal; PN, postnatal day; PCP, phencyclidine. 
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1.9 Summary 
Disturbances to the glutamatergic system are widely believed to contribute to the 
pathogenesis of schizophrenia. In particular, genetic and environmental evidence 
indicates neurodevelopmental disruption to the NMDA glutamate receptor may 
underlie the disorder. In line with this, pharmacological blockade of the NMDA receptor, 
with antagonists such as PCP, during development produces behaviours and 
neurochemical alterations analogous to schizophrenia. Therefore, this paradigm 
provides a model of schizophrenia, to examine the underlying pathogenesis and 
investigate potential new treatments.  
 
The NMDA receptor has been shown to share a physical and functional interaction with 
group 1 mGluRs (mGluR1 and mGluR5). mGluR1 and mGluR5 are 7-transmembrane 
spanning glutamate receptors that positively couple to Gq/11 and form individual 
homodimers, which is vital for their downstream signalling. Furthermore, they are 
important regulators of glutamatergic transmission, brain development and play a role 
in a wide variety of behaviours, most notably cognitive function, processes implicated in 
the pathology of schizophrenia. Moreover, genetic deletion of mGluR1 or mGluR5 in 
rodent models induces schizophrenia-like behaviours. Therefore, it is conceivable group 
1 mGluRs may contribute to the pathogenesis of schizophrenia.   
 
Recent postmortem studies reported altered expression of group 1 mGluRs in the 
prefrontal cortex and hippocampus, regions that send glutamatergic projections to the 
nucleus accumbens. Whilst the nucleus accumbens has previously been associated with 
dopaminergic alterations, recent investigation in low powered postmortem cohorts 
indicate the nucleus accumbens exhibits glutamatergic abnormalities in schizophrenia. 
Furthermore, a large body of work in rodent models indicates that current 
antipsychotics, which primarily target the dopaminergic system, alter glutamatergic 
tone within the nucleus accumbens. However, further research is required to 
characterise the glutamatergic system in the nucleus accumbens, in regards to the 
pathology and current pharmacological treatment of schizophrenia.  
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In addition to exploring group 1 mGluRs in the pathology of schizophrenia, recent drug 
discovery efforts have focused on these receptors as novel targets as an avenue to 
upregulate NMDA receptor deficits associated with schizophrenia. In particular, mGluR5 
PAMs such as CDPPB, have been shown to potentiate NMDA receptor currents and 
attenuate schizophrenia-like behaviours, in particularly cognitive deficits, in rodent 
models. Furthermore, CDPPB administration has also demonstrated potential for the 
treatment of other neurological and neuropsychiatric disorders such as autism, Rett 
syndrome, post-traumatic stress disorder, Huntington’s disease and addiction. 
However, there is still much unknown as to the molecular effects of CDPPB and other 
mGluR5 PAMs. Further understanding the underlying mechanisms, which may mediate 
their therapeutic efficacy, will assist in the development of these compounds for clinical 
suitability. 
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1.10 Aims and Hypotheses 
1.10.1 General Aim: 
To investigate group 1 mGluRs in the pathology and treatment of schizophrenia, in 
addition to their therapeutic potential. 
1.10.2 Specific Aims: 
1. To characterise the protein expression of group 1 mGluR and their endogenous 
regulators in the nucleus accumbens (a region associated with the positive 
symptoms of schizophrenia and regarded as critical for the therapeutic action of 
current antipsychotics) of a postmortem schizophrenia cohort.   
 
2. To determine the short- and long-term effect of commonly used antipsychotic 
treatments on the protein expression of group 1 mGluRs and their endogenous 
regulators, in the nucleus accumbens of a rodent model. 
 
3. To examine the neurodevelopmental profile of group 1 mGluRs and their 
endogenous regulators, and determine how this profile is altered in the perinatal 
PCP rodent model of schizophrenia. 
 
4. To investigate the short- and long-term effects of chronic adolescent CDPPB 
treatment on glutamatergic receptor expression within the frontal cortex and 
hippocampus. 
1.2.3 Rationale and Hypotheses 
1. Recent evidence from the McCollum group has indicated glutamaterigic 
abnormalities in the nucleus accumbens in schizophrenia, including reports of 
altered protein expression of the glutamate vesicle transporter, VGLUT2 and 
glutamate projections onto the nucleus accumbens. Furthermore, our previous 
findings show altered group 1 mGluR expression in the dorsolateral prefrontal 
cortex and hippocampus, regions that project onto the nucleus accumbens. 
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Therefore, it was hypothesised that glutamatergic receptors would be disrupted 
in the nucleus accumbens in schizophrenia.   
 
2. The extensive work from de Bartolomeis and colleagues reports typical and 
atypical antipsychotics can alter mRNA expression of striatal mGluR5 and its 
endogenous regulator, Homer1, in particular Homer1a. Therefore, it was 
hypothesised that typical and atypical antipsychotics would alter protein 
expression of group 1 mGluRs and Homer1 expression in the nucleus accumbens.  
 
3. Despite group 1 mGluR subtypes sharing many commonalities in structure and 
G-protein coupling and pharmacology, recent evidence highlights differences 
between the localisation, downstream signalling and receptor interactions 
between mGluR1 and mGluR5. These variances are supported by previous 
evidence indicating divergent mRNA transcript expression throughout 
neurodevelopment and following acute administration of NMDA receptor 
antagonists. Therefore, it was hypothesised mGluR1 and mGluR5 protein levels 
will exhibit unique patterns of neurodevelopmental expression, which will 
perinatal PCP treatment. 
 
4. Acute and chronic administration of the mGluR5 PAM, CDPPB, in adult and 
adolescent rodents has shown cognitive enhancing effects. Furthermore, the 
behavioural effects of adolescent CDPPB administration have shown to extend 
into adulthood, weeks after the cessation of treatment. In adult rodents treated 
with CDPPB, there is evidence these behavioural effects are mediated via 
CDPPB’s ability to upregulate glutamatergic signalling, in particular via the NMDA 
and AMPA receptor. Therefore, it was hypothesised chronic adolescent CDPPB 
treatment will have short- and long-term effects on glutamatergic signalling. 
Specifically, due to the known interaction of mGluR5 and the NMDA and AMPA 
receptor, CDPPB will change the expression of these receptors. 
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1.11 Significance 
Schizophrenia is a chronic and debilitating disorder that affects approximately 1% of the 
world’s population. Current treatments for schizophrenia primarily target the 
dopaminergic system, particularly within the nucleus accumbens. However, these 
compounds do not adequately treat all symptoms. The absence of an effective 
treatment for schizophrenia is largely due to a lack of understanding regarding the 
neurochemical underpinnings of the disorder. There is growing evidence that 
disturbances to the development and function of the glutamatergic system could 
contribute to the pathogenesis of schizophrenia.  
 
This thesis addresses whether the family of glutamatergic receptors, group 1 mGluRs 
and their expression in schizophrenia, particularly within the nucleus accumbens is 
altered and if they are affected following treatment with antipsychotic medication. 
Furthermore, this thesis will investigate the neurodevelopmental expression of group 1 
mGluRs within a rodent model of schizophrenia and provide an understanding of how 
group 1 mGluRs may participate in the pathogenesis of schizophrenia. In addition, this 
neurodevelopmental approach may identify potential neurodevelopmental windows 
where targeting these receptors, in particular mGluR5, may be therapeutically 
advantageous. Finally, this study will examine the neurochemical effect of adolescent 
CDPPB treatment to assist with the molecular understanding of mGluR5-targeting 
compounds and aid their preclinical development in an effort to find novel and effective 
treatment strategies for schizophrenia.   
 






2.1 Study rationale and aims 
Previous immunoblot investigation of postmortem tissue from our laboratory indicate 
increased mGluR1 and mGluR5 protein expression in the hippocampus of schizophrenia 
subjects. In addition, we also report schizophrenia subjects exhibit increased mGluR5 
protein expression in the dorsolateral prefrontal cortex. Furthermore, previous 
postmortem investigation of the dorsolateral prefrontal cortex and hippocampus have 
also reported NMDA receptor deficits, further supporting altered glutamatergic 
signalling to these brain regions. These regions send projections to the nucleus 
accumbens, which recent postmortem studies suggests exhibits glutamatergic 
alterations associated with schizophrenia. Chapter 2 aimed to explore if the recent 
glutamatergic alterations reported in the nucleus accumbens of schizophrenia subjects 
extends to the protein expression of group 1 mGluRs and NMDA receptors. 
 
2.2 Manuscript details 
The results of Chapter 2 are published in the Journal of Psychiatry and Neuroscience, 
entitled “A postmortem analysis of NMDA ionotropic and group 1 metabotropic 
glutamate receptors in the nucleus accumbens in schizophrenia”.  
 
2.3 Author contributions 
J. Lum performed the experiments, acquired and analysed the data, wrote the first draft 
of the manuscript, which all authors reviewed and approved for publication. 
 
 
Jeremy Lum 72 
 
2.4 Collaborator’s statement 
We hereby declare that the statement in Section 2.3 pertaining to the contributions of 
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3.1 Study rationale and aims 
The results from Chapter 2 indicate the protein expression of group 1 mGluRs is not 
altered in the nucleus accumbens of a large schizophrenia postmortem cohort. 
However, previous evidence indicates commonly used antipsychotic compounds can 
alter glutamatergic tone in the nucleus accumbens, indicating the results of Chapter 2 
may be influenced by premortem antipsychotic use. Further supporting this notion, a 
large body of work in rodents, suggest antipsychotics may alter group 1 mGluR signalling 
and localisation, as administration of the typical and atypical antipsychotics, haloperidol 
and aripiprazole, have shown to alter the mRNA expression of group 1 endogenous 
regulators such as Homer1. However, it has yet to be examined if this translates into 
changes to respective protein levels. Chapter 3 aimed to investigate the effect of short- 
and long-term antipsychotic treatment on the protein expression of group 1 mGluRs and 
their endogenous regulators (Homer1a, Homer1b/c and Norbin) in the nucleus 
accumbens of a rodent model. 
 
3.2 Manuscript details 
The results of Chapter 3 are published in Psychiatry Research, entitled “Effects of short- 
and long-term aripiprazole treatment on group 1 mGluRs in the nucleus accumbens: 
Comparison with haloperidol”.  
 
3.3 Author contributions 
J. Lum performed the experiments, acquired and analysed the data, wrote the first draft 
of the manuscript, which all authors reviewed and approved for publication. 
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We hereby declare that the statement in Section 3.3 pertaining to the contributions of 
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4.1 Study rationale and aims 
The results from Chapter 2 and previous postmortem results reported by our laboratory 
indicate dysregulation of group 1 mGluRs in schizophrenia may be localised to the 
prefrontal cortex and hippocampus (Matosin et al., 2015b, 2015c, 2016a), rather than 
the nucleus accumbens. Therefore, the following Chapters focused on exploring the role 
of group 1 mGluRs in the prefrontal cortex and hippocampus in the pathogenesis and 
treatment of schizophrenia. 
 
Postmortem tissue provides a valuable tool to investigate pathological alterations 
associated with schizophrenia, however only provides a snapshot of the end stage of 
disease. The pathogenesis of schizophrenia is widely believed to be 
neurodevelopmental in origin and derived from glutamatergic alterations through 
critical stages of neurodevelopment. Group 1 mGluRs play an integral role in many 
neurodevelopmental processes, many of which are thought to be disrupted in 
schizophrenia. In an attempt to understand the neurodevelopmental role of group 1 
mGluRs and their implication in neurodevelopmental disorders, several studies have 
investigated the protein expression of group 1 throughout human and rodent 
neurodevelopment using immunoblotting techniques. However, previous studies have 
examined group 1 mGluRs under reducing conditions and only examined their 
respective monomeric bands and disregarding the dimeric form, which is now widely 
believed to be their functional unit. Chapter 4 aimed to investigate the protein 
expression of group 1 mGluRs, in particular their dimeric and monomeric form, in the 
frontal cortex and hippocampus at critical stages of neurodevelopment (juvenile, 
adolescence and adulthood) and how this may be altered in the perinatal PCP model of 
schizophrenia.   
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4.2 Manuscript details 
The results of Chapter 4 are published in Scientific Reports entitled, 
“Neurodevelopmental expression profile of dimeric and monomeric group 1 mGluRs: 
Relevance to schizophrenia pathogenesis and treatment”.  
 
4.3 Author contributions 
J. Lum performed the experiments, acquired and analysed the data, wrote the first draft 
of the manuscript, which all authors reviewed and approved for publication. Rodents 
were treated and tissues obtained by K. Newell, N. Matosin, F. Fernandez and J. 
Andrews; brain tissue was processed and analysed by J. Lum.  
 
4.4 Collaborator’s statement 
We hereby declare that the statement in Section 4.3 pertaining to the contributions of 
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5.1 Study rationale and aims 
Recent evidence indicates mGluR5-stimulation, with PAMs such as CDPPB, may provide 
a novel therapeutic strategy for the treatment of schizophrenia and other 
neurodevelopmental disorders such as autism. Early intervention is proposed to be 
therapeutically advantageous for schizophrenia and other neurodevelopmental 
disorders. The results from Chapter 4 indicate monomeric mGluR5 expression is 
relatively high during early neurodevelopmental periods and may not be a suitable 
therapeutic window for PAM administration, as it may produce agonist-like activity. 
However, adolescence may provide a more suitable therapeutic window for PAM 
intervention. In line with this, recent studies have shown mGluR5 PAM administration 
during adolescence can prevent schizophrenia-like behaviours into adulthood. However, 
there is little molecular understanding of the short- and long-term effects of mGluR5 
PAMs, which may underlie their therapeutic efficacy. Chapter 5 aimed to explore the 
effect of adolescent CDPPB treatment on glutamatergic receptor expression in the 
frontal cortex and hippocampus of adolescent and adult rodents.  
 
5.2 Manuscript details 
The results of Chapter 5 are published in Neurochemical Research entitled, “Chronic 
adolescent CDPPB treatment alters short-term, but not long-term, glutamatergic 
receptor expression”.  
 
5.3 Author contributions 
J. Lum performed the experiments, acquired and analysed the data, wrote the first draft 
of the manuscript, which all authors reviewed and approved for publication. 
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We hereby declare that the statement in Section 5.3 pertaining to the contributions of 
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6.1 Overall discussion  
The past five decades of schizophrenia research have strongly pointed to disrupted 
development of the glutamatergic system, in particular the NMDA receptor, in the 
pathogenesis of schizophrenia. More recently, evidence from human and animal studies 
supports a role for the group 1 mGluRs, which physically and functionally interact with 
the NMDA receptor (Matosin and Newell, 2013). In line with this, current efforts to 
develop group 1 mGluR-targeting compounds, in particular, mGluR5, are being pursued 
as a novel therapeutic for schizophrenia, in addition to other neurodevelopmental 
disorders. The present work aimed to investigate the role of group 1 mGluRs in the 
development and pathophysiology of schizophrenia, as well as examining the 
neurochemical changes induced by the mGluR5 PAM, CDPPB.  
 
Postmortem tissue provides an important tool to investigate and understand the 
pathology of neurological and neuropsychiatric disorders. Evidence from postmortem 
studies investigating the protein expression of group 1 mGluR has been varied and 
limited to elderly cohorts and low-powered sample size (summarised in Section 1, Table 
1.2). However, our research group recently reported increased protein expression of 
mGluR5 in the dorsolateral prefrontal cortex and altered mGluR1 and mGluR5 levels in 
the hippocampus of adequately powered postmortem cohorts (Matosin et al., 2015b, 
2015c, 2016a). Although the aforementioned studies were performed under reducing 
conditions, which can reduce dimeric mGluR disulphide bonds to their respective 
monomeric forms, these changes were greater or specifically related to the dimeric form 
of mGluR1 or mGluR5. Interestingly, recent evidence indicates the dimeric form of 
mGluRs to be the functional signalling unit (El Moustaine et al., 2012).  
 
In an effort to follow on from our previous studies and address dimeric/monomeric 
protein levels, Chapter 2 sought to investigate the protein expression of group 1 mGluR 
monomeric and dimeric forms in the nucleus accumbens of a schizophrenia postmortem 
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cohort. As discussed in Chapters 1 and 2, whilst the nucleus accumbens has historically 
been associated with dopaminergic abnormalities in schizophrenia, recent in vivo 
imaging studies indicate these abnormalities may not be as prominent as previously 
thought (Howes et al., 2009; Kegeles et al., 2010). Furthermore, recent postmortem 
evidence suggests the nucleus accumbens exhibits altered glutamatergic tone 
(McCollum et al., 2016; McCollum and Roberts, 2015). The nucleus accumbens is a 
region of convergence for the dorsolateral prefrontal cortex and hippocampus, where 
we previously reported altered group 1 mGluR expression. Furthermore, prefrontal 
cortical glutamatergic afferents onto the nucleus accumbens signal via mGluR1 and 
mediate motivational behaviour (Turner et al., 2018), a common symptom reported in 
schizophrenia patients. Utilising the largest nucleus accumbens postmortem cohort to 
date, the present study reported no significant change in the total, dimeric or 
monomeric protein expression of either mGluR1 and mGluR5 in schizophrenia subjects, 
in line with a previous study investigating total mGluR1 and mGluR5, in a smaller cohort. 
In addition, no differences were observed in the protein expression of the group 1 
mGluR endogenous regulators, Norbin and Homer1b/c. Furthermore, there was also no 
difference in the protein expression of NMDA receptor subunits, NR1, N2A and NR2B, in 
line with previous mRNA and binding studies (Aparicio-Legarza et al., 1998; Meador-
Woodruff et al., 2001; Noga et al., 1997). Collectively, the present and previous results 
examining group 1 mGluRs, NMDA receptors and other glutamatergic receptors in the 
nucleus accumbens, do not support the recent findings from McCollum and colleagues 
suggesting glutamatergic abnormalities in this region. However, it should be noted that 
McCollum reported an increase of glutamatergic synapses specifically within the core 
and not shell of the nucleus accumbens, whereas the present study and previous studies 
have not separated these subregions. Whilst neither study strongly supports nor rejects 
glutamatergic dysfunction within the nucleus accumbens, further studies should be 
undertaken to explore this notion. 
 
A large majority of schizophrenia postmortem studies report positive findings in the 
dorsolateral prefrontal cortex and hippocampus. However, this may be largely due to 
the fact these are areas most extensively investigated. Furthermore, a limititation of 
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many postmortem studies is the absence of follow-up investigations in other brain 
regions to determine if observed alterations are global or selective. We previously 
reported increased mGluR5 expression in the dorsolateral prefrontal cortex and 
hippocampus of schizophrenia subjects (Matosin et al., 2015b, 2015c). Chapter 2 
followed on from these findings to examine mGluR5 expression in the nucleus 
accumbens, a brain region that receives dense innervation from both the dorsolateral 
prefrontal cortex and the hippocampus (Britt et al., 2012). A significant number of 
subjects analysed in our previous studies were included in Chapter 2 (Table 6.1), 
providing the opportunity to examine if mGluR5 expression was correlated between 
brain regions and identify if alterations in projecting regions, may influence nucleus 
accumbens expression. It was postulated that mGluR5 expression might be increased in 
the nucleus accumbens of subjects that exhibited increased expression in the 
dorsolateral prefrontal cortex and hippocampus, indicating a global increase in mGluR5 
levels. However, Spearman’s correlations revealed no significant association of mGluR5 
protein levels between the brain regions (Table 6.2). Furthermore, analysis of mGluR5 
expression in the dorsolateral prefrontal cortex, hippocampus and nucleus accumbens 
of the same subjects revealed no significant diagnostic difference in the nucleus 
accumbens (Figure 6.1a), despite this subset of schizophrenia subjects still exhibiting 
significantly increased mGluR5 expression in the dorsolateral prefrontal cortex and 
hippocampus (Figure 6.1b-c), as previously reported (Matosin et al., 2015b, 2015c). This 
indicates that mGluR5 expression is not globally increased in schizophrenia and in line 
with many other studies that suggest glutamatergic changes are largely present in 
cortical and hippocampal regions with scarce reports of changes in the nucleus 
accumbens. It is unclear, why the dorsolateral prefrontal cortex and hippocampal 
regions may be more sensitive to glutamatergic alterations or why the nucleus 
accumbens is immune, particularly considering many cortical and hippocampal 
glutamatergic efferents project onto the nucleus accumbens. However, the reason may 
lie in the cytoarchitectural heterogeneity between the regions. The dorsolateral 
prefrontal cortex and hippocampus are highly comprised of pyramidal cells and 
interneurons (Lewis, 2004; Slomianka et al., 2011), whilst the nucleus accumbens 
primarily consists of medium spiny neurons (Britt et al., 2012). Our studies to date have 
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yet to investigate if a specific cell type(s) may be responsible for the observed increases 
in mGluR5 expression within the dorsolateral prefrontal cortex and hippocampus, 
however obtaining this knowledge would aid in further dissecting the underlying 
pathology of schizophrenia. Nevertheless, it seems dysregulation of mGluR5 may not 
apply universally or influence the expression of mGluR5 in projecting regions, however 
it should be considered whether it is localised to specific cell types; further examination 
on this, preferably within the same cohort of subjects, is warranted. 
 
Table 6.1: Summary of postmortem subject demographics included from our 
laboratory’s analysis of the nucleus accumbens, dorsolateral prefrontal cortex and 







Age at death (years) 58.75±13.72 52.46±13.93 1.219 0.233 
Postmortem interval (hours) 25.75±12.78 29.65±11.44 -0.857 0.399 
Brain pH 6.53±0.25 6.56±0.24 -0.338 0.738 
Freezer Storage time (days) 3753±871 4147±617 -1.421 0.167 
Hemisphere 11 Right, 5 Left 8 Right, 5 Left   
Gender 14M, 2F 7M, 6F   
Values are represented as mean±SEM. M: males; F: Females.  
 
 
Table 6.2: Spearmans’s correlations for associations of total mGluR5 protein levels between 
the nucleus accumbens (NAcc), dorsolateral prefrontal cortex (DLPFC) and hippocampus 
(cornu ammonis; CA1) 
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Figure 6.1: Total metabotropic glutamate receptor 5 (mGluR5) protein levels in the a) 
nucleus accumbens, b) dorsolateral prefrontal cortex and c) hippocampus (CA1; cornu 
ammonis 1) between schizophrenia (squares) and control groups (circles). *p<0.05 and 
*** p<0.001.  
 
Despite the lack of glutamatergic changes observed in Chapter 2, the nucleus accumbens 
is still highly regarded as a region of interest within schizophrenia research, due to 
evidence indicating it is a target area for mediating the actions of dopaminergic 
antipsychotic drugs. Whilst the results of Chapter 2 indicated no evidence of altered 
group 1 mGluR protein expression in schizophrenia, we cannot disregard the potential 
effect of premortem antipsychotic medication within the schizophrenia cohort. The 
daily lifetime chlorpromazine equivalent value for each subject is often used to associate 
the relationship between premortem antipsychotic use and investigated variables. In 
this study, daily lifetime chlorpromazine equivalent values showed no association with 
protein levels of group 1 mGluRs or NMDA receptor subunits, neurochonrin or 
Homer1b/c protein levels. Chlorpromazine equivalent value is defined as the dosage of 
antipsychotic, which has equivalent D2 receptor occupancy and antipsychotic potency 
to 100 mg of chlorpromazine (Woods, 2003). Whilst chlorpromazine equivalent values 
can provide an indication of premortem antipsychotic use, these results should be 
interpreted with caution, for several reasons.  Equivalent values are largely based on D2 
receptor occupancy and do not take into account the occupancy of other receptor types, 
which for atypical antipsychotics, are thought vital for their efficacy. Furthermore, the 
correlation between antipsychotic dose and antipsychotic efficacy may not be linear, as 
evidence suggests the relative potency of the typical antipsychotic, haloperidol declines 
as the dose increases (Foster, 1989). For this reason, animal models can provide a useful 
tool to not only dissect the mechanisms of actions of these compounds, but also to aid 
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our understanding of whether postmortem human findings are a true indication of 
disease pathology or may be the result of premortem antipsychotic treatment. 
 
The results of Chapter 3 showed that short- and long-term treatment with the typical 
and atypical antipsychotics, haloperidol and aripiprazole, did not alter group 1 mGluR 
protein levels in the nucleus accumbens in a rodent model. Previous examination of this 
model has shown NR1 protein expression to be upregulated in the nucleus accumbens 
following haloperidol and aripiprazole treatment (Pan et al., 2016). This is in line with 
similar results suggesting glutamatergic tone in the nucleus accumbens is altered 
following antipsychotic treatment (Fitzgerald et al., 1995; Healy and Meador-Woodruff, 
1997; Pan et al., 2016; Schmitt et al., 2003; Spurney et al., 1999). Particularly, previous 
evidence indicates ionotropic glutamate receptors are more prone to expression 
changes following antipsychotic treatment, whilst there is little evidence to suggest 
changes to group 1 mGluRs. This is unexpected, considering the evidence supporting a 
physical and functional link between D2 receptors and group 1 mGluRs, in particular, 
mGluR5 (Mao and Wang, 2016). Furthermore, agonist stimulation of mGluR5 has been 
shown to reduce D2 receptor agonist binding, suggesting a close functional association 
(Servaes et al., 2017). Despite, the lack of change in protein expression of group 1 
mGluRs reported in Chapter 3, Homer1a and Norbin expression were increased 
following antipsychotic treatment.  The present study is the first to examine the protein 
expression of Homer1 following antipsychotic treatment. However, the present results 
are in line with studies from de Bartolomeis and colleagues that have repeatedly 
reported changes to Homer1 mRNA expression following antipsychotic treatment 
(Ambesi-Impiombato et al., 2007; de Bartolomeis et al., 2002, 2013; Iasevoli et al., 
2010a, 2010b, 2011; Tomasetti et al., 2007). Homer1 and Norbin have been shown to 
regulate the localisation and signalling of group 1 mGluRs. This may indicate that whilst 
group 1 mGluR protein levels are unchanged, their localisation and signalling in the 
nucleus accumbens may be altered following antipsychotic treatment. However, further 
studies investigating the interaction of these proteins and the potential biological 
consequences will be required to understand the potential effect of antipsychotic 
treatment for group 1 mGluR signalling and if this mediates the action of antipsychotics.  
 
Jeremy Lum 129 
 
 
Collectively, Chapters 2 and 3 aimed to further build on previous findings from our 
laboratory regarding altered expression of group 1 mGluRs and investigate if similar 
alterations were observed in the nucleus accumbens, a region highly implicated in the 
pathogenesis of schizophrenia. However, the findings presented here provide little 
support of similar alterations that we had previously observed in the dorsolateral 
prefrontal cortex and hippocampus, indicating brain-region specific differences. Whilst 
the present data cannot eliminate the possibility that glutamatergic alterations exist in 
the nucleus accumbens, previous evidence from our own lab and others provide 
stronger support for glutamatergic alterations in cortical and hippocampal regions. In 
line with this, the majority of previous examinations of group 1 mGluRs in schizophrenia 
have focused on its implication in associated cognitive deficits. Furthermore, 
investigation of mGluR5 as a novel therapeutic target has largely focused on its ability 
to enhance cognitive processes, primarily mediated by cortical and hippocampal 
regions, collectively suggesting group 1 mGluRs may play a larger role in these regions, 
rather than subcortical regions, like the nucleus accumbens. Based on these brain-region 
specific effects, Chapters 4 and 5 focused on the role of cortical and hippocampal group 
1 mGluRs in regards to the pathology and treatment of schizophrenia. 
 
Chapter 4 explored the neurodevelopmental expression of group 1 mGluRs, specifically 
in the perinatal PCP model, a well-established neurodevelopmental model of 
schizophrenia. This model has previously shown to produce alterations in NMDA 
receptor expression and phosphorylation, a reflection of altered glutamatergic signalling 
and in line with the glutamatergic hypothesis of schizophrenia (Anastasio and Johnson, 
2008a, 2008b; du Bois et al., 2012; Wang et al., 2001). Analysis of group 1 mGluRs in this 
model revealed mGluR1 dimer expression was reduced in the hippocampus at PN12, 
following perinatal PCP exposure, whilst mGluR5 protein levels were increased at the 
same time-point in the frontal cortex and hippocampus. As previously, described 
mGluR5 has a strong physical and functional link with the NMDA receptor and was 
previously shown to upregulate NMDA receptor activity. Furthermore, early postnatal 
administration with the NMDA receptor antagonist, MK-801 has previously shown to 
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acutely increase mGluR5 mRNA expression (Wilson et al., 1998). Collectively, this may 
suggest mGluR5 expression/activity may be upregulated following NMDA receptor 
blockade, as a compensatory mechanism. Interestingly, the upregulation of mGluR5 
protein was only observed to the dimeric form, which is known to be the functional 
signalling unit for mGluRs, highlighting the importance of measuring this form.  
 
A growing body of evidence clearly supports that mGluR dimerisation is vital for 
traditional agonist-induced downstream signalling (El Moustaine et al., 2012; Kniazeff et 
al., 2004). Therefore, throughout this thesis, particular effort was made to quantify 
mGluR1 and mGluR5 protein expression under non-reducing conditions, to ensure 
quantification of the dimeric bands. Immunoblots of mGluR1 or mGluR5 under non-
reducing conditions exhibited three separate bands. One band was observed at 
approximately 150kDa, representing the monomeric form of the receptors. 
Furthermore, two distinct bands were observed and migrated at approximately 270-280 
kDa represent the dimeric form of these receptors. To validate the specificity of these 
dimeric bands, two additional antibodies for mGluR1α and mGluR5, (MAB07-617 and 
Ab5675, respectively) were used. These antibodies recognise separate epitopes than the 
antibodies used throughout this thesis however, showed a similar pattern of binding 
where two dimeric bands were observed for mGluR1 and mGluR5 (Figure 6.2a-b). This 
provides strong evidence that these bands do represent specific mGluR1 and mGluR5 
proteins. Furthermore, the presence of these two distinct dimeric bands has previously 
been reported by others and specificity confirmed in respective KO mice (Ayala et al., 
2012; Kirschstein et al., 2007; Lee et al., 2015). However, it is unclear what these two 
dimeric bands may represent.  These two dimer bands are unlikely to represent splice 
variants, as although mGluR5 has two isoforms of similar molecular weight (mGluR5a; 
128 kDa and mGluR5b; 132 kDa), mGluR1 does not have a splice variant of a similar 
molecular weight to mGluR1α (132 kDa) (Ferraguti et al., 2008). However, post-
translational modifications including ubiquitination, phosphorylation, palmitylation and 
glycosylation can cause proteins to migrate differently to their predicted molecular 
weight (Bass et al., 2017). These post-translational modifications can influence a 
protein’s function, trafficking and localisation and therefore are of value to investigate. 
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In fact, the glycosylation of several glutamatergic proteins including the AMPA receptor 
subunit, GluA2 and excitatory amino acid transporters, EAAT1 and EAAT2 have been 
reported to be altered in schizophrenia (Bauer et al., 2010; Tucholski et al., 2013). 
mGluR1/5 contain several N-linked glycosylation sites, particularly at the N-terminus, 
that could increase their expected molecular weight and may subsequently represent 
the two dimer bands (glycosylated and glycosylated mGluR1/5) (Bhave et al., 2003). 
However, incubation of tissue with the N-linked deglycosylation enzyme, Peptide:N-
Glycosidase F (PNGase F) and subsequent immunoblot of mGluR5, showed both dimeric 
bands were sensitive to PNGase treatment (Figure 6.2c). Whilst this does not suggest 
the bands represent different N-linked glycosylation status, it does not eliminate other 
forms of glycosylation or post-translational modifications. Further investigation to 
determine the exact nature of these bands may highlight differences in the function, 
trafficking or localisation of group 1 mGluRs. 
 
 
Figure 6.2: Immunoblots of rodent cortical tissue with a. mGluR1 (MAB07-617) and b. 
mGluR5 (ab5675), show two bands (indicated by arrows) at a molecular weight 
corresponding to the molecular weight of the dimeric mGluR1α/5, similar to the pattern 
observed from the antibodies used throughtout this thesis. c. Adult rat cortical 
homogenate was incubated with the deglycosylation enzyme, PNGase F (1 or 10 
units/10 ug homogenate) for 3 hours. PNGase F treated homogenate was then 
separated by electrophoresis and proteins were transferred onto PDVF membrane. 
Membranes were subsequently incubated with anti-mGluR5 antibody (ab27190). 
Immunoblots revealed that pre-treatment of rat tissue PNGase F (10 units), caused a 
molecular weight shift in both dimeric bands of mGluR5. kDa, kilodaltons. 
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Whilst there have been several studies investigating the neurodevelopmental profile of 
group 1 mGluRs, none to date were performed under non-reducing conditions and 
investigated the dimeric:monomeric form of these proteins. Chapter 4 clearly shows the 
importance of examining this, as it was evident that the monomeric form of mGluR5 is 
highly abundant at PN12 in all brain regions examined (hippocampus, frontal cortex and 
nucleus accumbens), compared to the later time points examined (PN35 and PN96), 
where it was almost undetectable, irrespective of perinatal PCP treatment. This is the 
first report of an mGluR, showing such a stark neurodevelopmental change in 
dimeric:monomeric expression. Furthermore, it appeared to be restricted to mGluR5, as 
analysis of mGluR1 did not show a similar trend. However, it is also unclear why we 
observed this trend, as dimerisation of mGluRs is complex and still not well understood. 
However, it is established that mGluR5 dimerises in the endoplasmic reticulum and Golgi 
apparatus (Pin et al., 2003). The high levels of monomeric mGluR5 observed during the 
juvenile period may represent newly synthesised and immature mGluR5 within the 
ribosomes, endoplasmic reticulum or Golgi apparatus, in preparation for post-
translational modification or heterodimerisation with other G-protein coupled 
receptors such as mGluR1, D2, A2A and calcium-sensing receptors. Furthermore, it may 
represent functional mGluR5 within a specific subcellular compartment, as work from 
Karen O’Malley’s group have clearly demonstrated mGluR5 is expressed on organelle 
membranes and plays a signalling role, including within the nuclear membrane (Jong et 
al., 2009; Jong et al., 2014; Kumar et al., 2008; O’Malley et al., 2003b; Sergin et al., 2017). 
Whilst the current study did not examine the expression of mGluR5 within subcellular 
fractions, it does not appear that mGluR5 monomer is highly abundant within the 
nuclear membrane (personal communication with Karen O’Malley); however, this is yet 
to be explored on other organelle membranes. Furthermore, recent evidence from our 
laboratory also showed that this high mGluR5 monomer expression is not specific to 
Sprague-Dawley rats, as we observed a similar trend in the Wistar-Kyoto strain of rats 
(Figure 6.3). However, it is unknown if this pattern of expression is conserved in other 
species.  It would be of particular interest to examine this in a neurodevelopmental 
human postmortem cohort, particularly as it may inform the potential use of mGluR5 
pharmaco-therapeutics during neurodevelopmental periods. As previously discussed, 
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dimerisation of mGluRs is vital for agonist-induced signalling, furthermore dimerisation 
appears integral for controlling PAM downstream activity. Whilst monomeric mGluRs 
are still able to couple to G-proteins, they are unable to elicit a downstream effect in the 
presence of the agonist, glutamate. However, the presence of PAMs was able to 
stimulate downstream activation of monomeric mGluR, in the absence of glutamate (El 
Moustaine et al., 2012). This could pose a major limitation to mGluR5 PAM 
development, as a major advantage of PAMs is their ability to only potentiate a response 
in the presence of an orthosteric ligand and avoid constant and elongated receptor 
stimulation, which is known to cause receptor desensitisation, excitotoxcity and 
seizures. Consequently, if PAMs were administered during a neurodevelopmental 
period of high monomeric mGluR5 expression, this could cause a wide array of 
neurotoxic effects. In fact, mGluR5 PAMs have been proposed to treat a wide range of 
neurodevelopmental disorders, such as autism, Rett syndrome and schizophrenia, 
where early intervention is thought to be advantageous. However, based from the 
evidence presented in Chapter 4, it is proposed mGluR5 PAM administration during early 
neurodevelopmental periods may have potential harmful effects. Therefore, further 
investigation of mGluR5 PAM administration during the juvenile period is warranted to 
examine for potential induction of cell death and excitotoxicity processes.  
 
 
Figure 6.3: Representative immunoblot images of mGluR5 in the frontal cortex of 
Sprague-Dawley (SD) and Wistar-Kyoto (WKY) rats at postnatal days (PN) 12, 35 and 96. 
kDa, kilodaltons.   
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The basis of mGluR5’s therapeutic potential for schizophrenia was originally thought to 
be due to its ability to modulate NMDA receptor activity (Kinney et al., 2005). In 
particular, administration of mGluR5 PAMs at adulthood, have shown to attenuate 
various schizophrenia-like behaviours in animal models. Based on the evidence in 
Chapter 4, we hypothesised targeting mGluR5 at adolescence may provide a beneficial 
treatment window, as there is little expression of monomeric mGluR5 at this timepoint 
and this age period when schizophrenia symptoms commonly begin to emerge.  
 
Chapter 5 aimed to investigate the short- and long-term effects of chronic adolescent 
CDPPB treatment, on glutamatergic receptor expression in the prefrontal cortex and 
hippocampus, two regions implicated in schizophrenia and involved in cognitive 
processes. Our study showed a general upregulation of the glutamatergic receptor 
proteins measured in the adolescent hippocampus, which included mGluR5, the NMDA 
receptor subunits, NR1, NR2A and NR2B and the AMPA receptor subunits GluA1 and 
GluA2. However, no changes to these proteins were observed in the adolescent 
prefrontal cortex, suggesting brain region specific effects of chronic adolescent CDPPB 
treatment. In line with this, previous studies have also reported CDPPB treatment 
caused brain region specific effects following acute and/or chronic administration at 
adulthood (Parmentier-Batteur et al., 2012; Uslaner et al., 2009).  Whilst it is unclear 
why CDPPB may have brain region specific effects, mGluR5 displays diverse cell type 
expression, protein interactions and subsequent signalling in different brain regions 
(Matosin et al., 2016), which may underlie the brain specific changes observed in 
Chapter 5. Further understanding the unique patterns of mGluR5 signalling and 
neurochemical changes caused specifically by various mGluR5 PAMs within certain brain 
regions, may inform drug discovery efforts for the variety CNS disorders mGluR5 PAM 
treatment has been proposed. 
 
Despite observing changes in the adolescent hippocampus following CDPPB treatment, 
similar changes at adulthood in the hippocampus or prefrontal cortex were not 
observed, indicating the current treatment model did not cause long-term changes to 
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the glutamatergic signalling, at least under the current treatment paradigm. In line with 
this, Parmentier-Batteur (2012) reported adult rats treated with daily CDPPB treatment 
at the same dose used in the present study for seven days was able to attenuate 
amphetamine-induced hyperlocomotive deficits. However, a group of rats treated for 
six days and subsequently withdrawn from treatment for one day did not show the same 
treatment effect, suggesting the effects of chronic CDPPB treatment are reversible. 
Using a lower dose of CDPPB (10 mg/kg), a previous study investigating the effect of 
chronic adolescent CDPPB treatment reported an ability to attenuate neonatal PCP 
induced social interaction behavioural deficits several weeks following the cessation of 
treatment (Clifton et al., 2013). Acute dosage studies indicate CDPPB displays an 
inverted U-shaped dose effect on cognitive performance and NMDA/AMPA receptor 
phosphorylation, consequently leading to the thought a lower dose of CDPPB such as 10 
mg/kg, might be more beneficial, than a higher 30 mg/kg dose (Uslaner et al., 2009). 
Whilst no study to date has examined a dose-dependent study for chronic 
administration of mGluR5 PAMs, it could be postulated that chronic treatment with a 
lower dose of 10 mg/kg will produce greater effects on behaviour and glutamatergic 
signalling, than the 30 mg/kg dose used in the present study. The dose chosen in this 
thesis was based on previous studies indicating this dose enhanced performance in 
spatial learning tasks and ameliorated NMDA receptor antagonist-induced cognitive set-
shifting deficits (Fowler, 2012; Stefani and Moghaddam, 2010). However, it should be 
noted these studies used an acute dose of CDPPB, with no study to date investigating a 
dose response in a chronic treatment paradigm. Whilst results from the present study 
do not support that adolescent CDPPB treatment causes long-term changes in regards 
to glutamatergic receptor expression, this does not exclude that short- or long-term 
changes could have occurred to other neurotransmitter or associated systems. CDPPB 
was shown to affect a wide array of neurotransmitter systems, including the 
dopaminergic and GABAergic systems, which are of high relevance to schizophrenia. A 
further understanding of the molecular and dose effects of CDPPB and other mGluR5 
PAMs will help improve drug design and development. 
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A large majority of studies investigating mGluR5 PAMs, have primarily focused on their 
ability to alter neurotransmitter deficits associated with schizophrenia. However, recent 
evidence indicates non-neuronal cells may play a more important role in the pathology 
of schizophrenia, than previously thought. Postmortem and imaging studies indicate 
that a subset of schizophrenia patients exhibit increased inflammatory markers and 
reduced hippocampal neural stem cells (Fillman et al., 2013; Reif et al., 2006). 
Furthermore, similar findings have also been reported in various animal models of 
schizophrenia (Kvajo et al., 2008; Nawa and Takei, 2006), highlighting the importance of 
non-neuronal types in the pathology of schizophrenia. mGluR5 is expressed on many cell 
types including neural stem cells, oligodendrocytes, astrocytes and microglia (Balázs et 
al., 1997; Melchiorri et al., 2007; van den Pol et al., 1995). Activation of mGluR5 
expressed on the aforementioned cell types has shown to be responsible for various 
functional roles and therefore may be a potential avenue for the therapeutic efficacy of 
mGluR5 PAMs, not only for schizophrenia, but also other neurological disorders where 
non-neuronal cells may be implicated. The mGluR5 PAM, VU0360172 has shown in vitro 
and in vivo evidence to suppress microglial proliferation and activation in a model of 
traumatic brain injury (Loane et al., 2014). In addition, evidence also indicates mGluR5 
activation is important for the activation of neural stem cell survival and proliferation 
within the hippocampus (Jansson and Åkerman, 2014). In line with this, administration 
of CDPPB (10 mg/kg daily; i.p) for three days increased the proliferation of neural stem 
cells and new neurons within the hippocampus (Nochi et al., 2012). Although, 
investigation of the effects of mGluR5 PAMs on glia and neural stem cells is still is in its 
infancy, these early studies open an extensive avenue for investigation and may provide 
alterative mechanisms for the therapeutic efficacy of mGluR5 PAMs. To date no studies 
have directly examined the ability of an mGluR5 PAM to attenuate microglial activation 
or neural stem cell proliferation in a rodent model of schizophrenia. However, 
considering the evidence supporting a beneficial role of mGluR5 PAMs in these 
processes, it warrants investigation and may provide further support for the use of 
mGluR5 PAMs in the treatment of schizophrenia.  
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6.2 Limitations 
Collectively, the work presented in this thesis provides further knowledge of group 1 
mGluRs and their endogenous regulators in the pathology and treatment of 
schizophrenia. However, several limitations need to be considered. 
 
The present work examined the protein expression of group 1 mGluRs, Norbin and 
Homer1 in various paradigms of the pathology and treatment of schizophrenia, by 
means of immunoblotting the aforementioned proteins within crude homogenates. 
There is now substantial evidence group 1 mGluRs are specifically localised on specific 
cell types (Byrnes et al., 2009; Luyt et al., 2003; Romano et al., 1996). Furthermore, 
depending on the cell type and proximity to other interacting proteins, such as the 
NMDA receptor, group 1 mGluRs signalling can be cell-type dependent. Whilst double 
labelling immunohistochemistry may shed light on any potential cell-specific changes of 
group 1 mGluR expression, it would not have allowed the examination of 
dimer:monomer levels. Recent advances in fluorescence-activated cell sorting or laser-
capture microdissection would allow the separation of cell types and analysis of 
dimer:monomer expression, however this approach requires large amounts of tissue, 
which is often not possible in human postmortem analyses, and the techniques have 
only been successful in a handful of laboratories. In addition to potential cell-type 
specific alterations, group 1 mGluRs play a varied role dependent on their subcellular 
localisation (Jong et al., 2017).  Group 1 mGluRs are localised on various organelle 
membranes, most notably the nucleus (Jong et al., 2007, 2005; Sergin et al., 2017). 
Whilst this study found no changes in group 1 mGluR protein expression in the nucleus 
accumbens of schizophrenia subjects and following antipsychotic treatment, the 
present work cannot exclude that there may be changes in their subcellular localisation. 
In particular, Chapter 3 shows Homer1a and Norbin, which can regulate mGluR5 cell 
surface localisation and downstream signalling, are altered following antipsychotic 
treatment. Considering Homer1a and Norbin are responsible for the localisation and 
signaling of group 1 mGluRs, particularly mGluR5, it is hypothesised the consequential 
upregulation of these endogenous regulators following antipsychotic treatment would 
increase group 1 mGluR cell surface expression and downstream signalling. 
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Furthermore, antipsychotic treatment has shown to cause synaptic remodelling, in 
which group 1 mGluRs and their endogenous regulators play an important role. 
Therefore, the upregulation of these proteins may be vital for antipsychotic-induced 
synaptic plasticity in the nucleus accumbens. However, future studies are required to 
characterise these findings in regards to protein localisation, interaction and potential 
biological consequence.  
 
The present work examined both the dimeric and monomeric forms of group 1 mGluRs; 
recent evidence indicates group 1 mGluRs can form heterodimers with each other 
(Doumazane et al., 2011; Pandya et al., 2016). Furthermore, there is also evidence that 
group 1 mGluRs can heterodimerise or at least co-localise and form higher order 
oligomer complexes with other GPCRs such as GABAB, D2, calcium-sensing and A2A 
receptors, which have also shown to have functional consequences on group 1 mGluR 
stimulation. In particular, mGluR5 shares an intriguing complex with A2A and D2 
receptors on striatopalldal GABAergic neurons found projecting from the nucleus 
accumbens. Stimulation of mGluR5 has shown to reduce D2 receptor agonist binding 
(Popoli et al., 2001). Furthermore, co-stimulation of A2A and mGluR5 decreases agonist 
binding to the D2 receptor greater than individual stimulation of either receptor (Popoli 
et al., 2001). In addition, perfusion of CHPG and the A2A receptor agonist, CGS 21680, 
has shown to increase localised GABA levels far larger than either agonist alone and 
similar to level of the D2 receptor antagonist, raclopride (Diaz-Cabiale et al., 2002). 
Collectively, it appears mGluR5/A2A/D2 receptors are capable of forming a functional 
complex. Whilst the present work did not aim to investigate these potential 
heterodimers, examining such heterodimers may provide more insight into the 
molecular complexities of psychiatric disorders. 
 
Chapter 5 aimed to investigate the neurochemical effects of adolescent CDPPB 
treatment. Whilst, this study provides valuable insight into the short-and long-term 
effects on glutamatergic receptor expression, there are several limitations. Firstly, no 
behavioural tests were performed to examine if CDPPB treatment showed any cognitive 
enhancing effects at adolescence or adulthood, analogous to that reported in previous 
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studies (summarised in Table 1.3). The addition of behavioural testing would have 
allowed a comparison with the molecular data presented in Chapter 5. Secondly, this 
study examined the protein expression of mGluR5, NMDA and AMPA receptor subunits, 
which may not accurately affect the active state. Previous studies suggest the 
phosphorylation of the receptor may be altered, without changes to protein expression 
(Parmentier-Batteur et al., 2012; Uslaner et al., 2009). Furthermore, CDPPB was 
administered to naïve animals and not a model of schizophrenia. However, the 
development of novel therapeutics requires knowledge of its effects under physiological 
and pathophysiological conditions. It is evident that utilising an animal model of 
schizophrenia, in addition to a model of autism, Rett syndrome or addiction could cause 
neurological changes that may influence the effect of CDPPB treatment on mGluR5 
signalling and general glutamatergic neurotransmission. Clifton et al., (2013) reported 
promising cognitive effects following adolescent CDPPB treatment within the perinatal 
PCP model of schizophrenia, alike the model presented in Chapter 4 of this thesis. The 
perinatal PCP model is an established and widely used rodent model of schizophrenia to 
examine the underlying neurochemical changes associated with schizophrenia and 
investigate the efficacy of novel therapeutic compounds. However, it is unlikely a single 
rodent model will encapsulate the heterogeneity of schizophrenia. In line with this, 
other models are emerging, which may be beneficial to model the diverse aspects and 
origins associated with schizophrenia. Therefore, these parameters should be 
considered when examining the efficacy of novel antipsychotics and interpreting 
pathological changes in animal models of schizophrenia.   
6.3 Future Directions 
The present work builds upon a foundation of investigation of group 1 mGluRs and their 
involvement in schizophrenia. However, as the field’s understanding of group 1 mGluRs 
continues to grow, there are still a multitude of avenues which should be considered for 
future studies. It is evident group 1 mGluRs are more complex than simple transmitter 
receptors capable of converting extracellular indicators toward intracellular signals. 
Recent evidence indicates mGluR5 is found within the nuclear membrane and physically 
interacts with chromatin (Sergin et al., 2017). However, the regions of DNA that mGluR5 
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may interact with are yet to be investigated, although techniques such as chromatin 
immunoprecipitation (CHIP)-seq, could help identify such regions. Furthermore, the 
functional consequence of this interaction has not been examined, however previous 
proteins identified to interact with chromatin, can regulate transcription and epigenetic 
changes to the genome. Epigenetic regulation is a rapidly expanding area of research 
and has previously been implicated in schizophrenia and other psychiatric disorders 
(Schuebel et al., 2016). Therefore, examination of the mGluR5 and chromatin interaction 
would not only provide a further understanding of mGluR5, but also its potential 
implication in neurodevelopmental and psychiatric disorders.  
 
Group 1 mGluRs have been implicated in schizophrenia, primarily based on their 
interaction with the NMDA receptor (Awad et al., 2000; Doherty et al., 1997, 2000; Jia 
et al., 1998; Mannaioni et al., 2001; Pisani et al., 2001). However, group 1 mGluRs have 
also shown to interact with the AMPA receptor and regulate their cell surface expression 
and activation (Kim et al., 2015; Nakamoto et al., 2007; Ugolini et al., 1999). Previous 
studies suggest that NMDA and AMPA receptor trafficking to the cell surface may be 
disrupted in schizophrenia, particularly in the cortex (Beneyto and Meador-Woodruff, 
2008; Hammond et al., 2010; Kristiansen et al., 2010). Furthermore, based on our 
previous investigation of mGluR5 and its endogenous regulators in the dorsolateral 
prefrontal cortex, it could be speculated similar trafficking deficits could occur in regards 
to mGluR5 (Matosin et al., 2015b). Whilst the present study investigated the expression 
of group 1 mGluRs, in conjunction with NMDA and/or AMPA receptor subunit 
expression, it did not examine the cellular localisation or direct interaction of these 
proteins at the cell surface. To date, no study has examined the cellular localisation of 
group 1 mGluRs in schizophrenia postmortem tissue or co-localisation/interaction with 
NMDA and AMPA receptors. Future studies investigating such parameters may provide 
deeper insight into the role group 1 mGluRs may play in the pathology of schizophrenia.  
 
Norbin has shown to regulate cell-surface expression of mGluR5 (Wang et al., 2009). 
Recent evidence indicates mGluR5 localisation to the nuclear membrane is dependent 
on the C-terminus region (amino acids 852-876) (Sergin et al., 2017), which is also a 
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region where Norbin interacts with mGluR5, consequently leading to the proposition 
Norbin may be involved in the localisation of mGluR5 to the nucleus. Nevertheless, in 
vivo and in vitro studies indicate Norbin is important for synaptic plasticity, of which 
deficits are observed in many neuropsychiatric disorders (Ohoka et al., 2001; Wang et 
al., 2015, 2009). In line with this, aside from group 1 mGluRs, Norbin has shown to 
interact with the guanine-nucleotide exchange factor, P-Rex1, which is involved in 
regulating cytoskeletal structure, further supporting Norbin’s role in cellular 
architecture (Pan et al., 2016). Norbin expression has repeatedly been reported to be 
altered in schizophrenia and major depression postmortem cohorts (Martins-de-Souza 
et al., 2012; Matosin et al., 2015a, 2015c; Mudge et al., 2008), with the present study 
(Chapter 2) being the only study thus far, not to report a pathological change, possibly 
related to the subcortical region examined. In addition, Norbin KO mice show 
schizophrenia and depression-like behaviours, further supporting its role in 
neuropsychiatric disorders (Wang et al., 2015, 2009). Whilst there is little understanding 
of its biological function, several questions remain regarding its involvement in 
neuropsychiatric disorders. Firstly, does Norbin regulate mGluR5 localisation to the 
nuclear membrane and does it regulate the expression of synaptic proteins via such a 
manner, as activation of nuclear mGluR5 has shown to activate genes associated with 
synaptic plasticity? Secondly, is Norbin’s interaction with mGluR5 critical to its 
involvement in synaptic plasticity or does Norbin interact with other synaptic proteins, 
which may mediate its effects on neurite outgrowth and synaptic plasticity? 
Immunoprecipitation of Norbin and subsequent mass-spectrometry of interacting 
proteins would be able to provide some insight. Whilst Norbin was discovered over two 
decades ago and has demonstrated an important biological role in synaptic plasticity, 
and associated disorders, a further understanding may help elucidate a more specific 
role in these disorders. 
 
CDPPB provided a major breakthrough as the first mGluR5 PAM suitable for in vivo use, 
capable of potentiating NMDA receptor currents and exhibiting efficacy in attenuating 
schizophrenia relevant behaviours in rodent models. Whilst preclinical investigation of 
CDPPB and mGluR5 PAMs is still ongoing, evidence suggests some mGluR5 PAMs, 
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including CDPPB, possess agonist-like activity, subsequently inducing adverse effects 
such as seizures and cell death that may be associated with excessive NMDA receptor 
activation (Kinney et al., 2005; Parmentier-Batteur et al., 2014). Whilst it was previously 
believed NMDA receptor potentiation was vital for the efficacy of mGluR5 PAMs, a new 
light has been shed on mGluR5 PAMs, with the development of VU0409551 from Jeff 
Conn and colleagues (Rook et al., 2015). VU0409551 is reported to produce 
antipsychotic-like and cognitive enhancing effects, via potentiation of mGluR5 
downstream signalling, but does not modulate NMDA receptor activity (Balu et al., 2016; 
Ghoshal et al., 2017; Rook et al., 2015). Furthermore, it does not produce cell death or 
seizure activity even at doses 100x higher than necessary to produce behavioural 
efficacy (Rook et al., 2015). VU0409951 is believed to produce a downstream signalling 
profile biased from previous mGluR5 PAMs (Rook et al., 2015). The work investigating 
VU0409551 is still in its infancy and the molecular mechanisms underlying it behavioural 
efficacy are not fully characterised, however provides promise for the continual 
development of mGluR5 PAMs, void of neurotoxic side effects and improved clinical 
suitability. 
 
Based on the promising behavioural evidence of mGluR5 PAMs, Roche recently 
conducted the first human safety and tolerability study for an mGluR5 PAM, RG7342. In 
a randomised, double-blind, adaptive study, 37 healthy male subjects were 
administered a single dose of RG7342 (ranging from 0.06-1.2 mg; oral) or placebo (Sturm 
et al., 2018). RG7342 was tolerated up to 0.6 (under fasted conditions) and 0.9 mg 
(under fed condition) in healthy subjects. However, a majority of subjects reported 
nausea and dizziness, which were associated with RG7342 plasma concentration. 
Furthermore, the estimated terminal half-life of RG7342 was >1000 hours, causing the 
investigators to predict it would take >4 months for RG7342 to reach a steady state 
concentration. Due to the severity of the RG7342 related symptoms and the 
unfavourable half-life of RG7342, the Roche investigators discontinued the 
development of RG7342.  This initial study does not bode well for the clinical 
development of mGluR5 PAMs. However, the fact mGluR5 PAMs display promising 
preclinical efficacy in the treatment of all symptoms domains of schizophrenia (Vinson 
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and Conn, 2012) continue to encourage the field to endure efforts to design and 
synthesis mGluR5 PAMs with improved in vivo suitability to continue their clinical 
development. 
 
6.4 Conclusion  
The present body of work provides original findings and further insight into the 
glutamatergic system, in particular, group 1 mGluRs in the pathology, development and 
treatment of schizophrenia. This work has built from human neurobiology and 
progressed to neurodevelopmental, neuropharmacology and culminated in a novel 
treatment strategy for schizophrenia, using a rodent model. The findings from 
postmortem human brain reveal no involvement, at least using the present measures, 
of the glutamatergic system in the nucleus accumbens in schizophrenia. Whilst further 
studies using more functional approaches are warranted (where possible in this type of 
tissue), the approach used in this thesis to examine the dimeric forms is an important 
step to understand the functional properties of group 1 mGluRs and their possible 
involvement in schizophrenia. Employing this approach throughout this thesis identified 
the unusually high monomeric expression at the juvenile age period, which may have 
implications for future therapeutic strategies for mGluR5 PAMs. Finally, this thesis 
indicates adolescent treatment with the mGluR5 PAM, CDPPB produces brain-region 
specific effects on the glutamatergic system, providing insight into the neurochemical 
changes which may underlie its behavioural efficacy.  Collectively, this thesis adds to the 
current body of research investigating the role of group I mGluRs in the pathology, 
current and potentially future treatment of schizophrenia. Unravelling the 
neurochemical changes that do or do not characterise schizophrenia and those 
important for therapeutic efficacy, are essential in developing our understanding of 
schizophrenia pathology and will consequently improve treatment approaches.
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